CA2192623C - Medication vial/syringe liquid/transfer apparatus - Google Patents
Medication vial/syringe liquid/transfer apparatus Download PDFInfo
- Publication number
- CA2192623C CA2192623C CA 2192623 CA2192623A CA2192623C CA 2192623 C CA2192623 C CA 2192623C CA 2192623 CA2192623 CA 2192623 CA 2192623 A CA2192623 A CA 2192623A CA 2192623 C CA2192623 C CA 2192623C
- Authority
- CA
- Canada
- Prior art keywords
- vial
- liquid
- coupling
- coupling end
- syringe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000012546 transfer Methods 0.000 title claims abstract description 59
- 239000007788 liquid Substances 0.000 title claims description 41
- 239000003814 drug Substances 0.000 title description 12
- 229940079593 drug Drugs 0.000 title description 3
- 238000010168 coupling process Methods 0.000 claims abstract description 98
- 238000005859 coupling reaction Methods 0.000 claims abstract description 98
- 230000008878 coupling Effects 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 24
- 238000004891 communication Methods 0.000 claims description 12
- 230000004888 barrier function Effects 0.000 claims description 2
- 230000001808 coupling effect Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 description 8
- 238000005187 foaming Methods 0.000 description 7
- 230000008520 organization Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000004308 accommodation Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000012815 thermoplastic material Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2096—Combination of a vial and a syringe for transferring or mixing their contents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
- A61J1/2006—Piercing means
- A61J1/201—Piercing means having one piercing end
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J2200/00—General characteristics or adaptations
- A61J2200/10—Coring prevention means, e.g. for plug or septum piecing members
Abstract
Liquid-transfer apparatus, and methodology employing the same, operatively interposable a syringe and a vial, and accommodating both a single-mouth-size (single-size), two-vial transfer procedure, and a two-mouth-size (two-size), two-vial transfer procedure. The apparatus includes a liquid-transfer device having a syringe-coupling end, a vial-coupling end, and liquid-passage structure effectively communicating between these ends. In the case of accommodating a single-mouth-size (single-size), two-vial procedure, only the liquid-transfer device is employed, and the same is sized with a vial-coupling end that is constructed for direct coupling to the top of the single-size vial which is used. In the case of accommodating a two-mouth-size (two-size), two-vial operation, the liquid-transfer device is employed along with a vial-coupling adaptor which is removably receivable in a connected relationship with the vial-coupling end in the device to adapt the same for coupling to the top of a vial having the smaller of the two sizes of vials which are to be employed. Under these circumstances, the entire procedure begins with coupling of the apparatus to a syringe and to the smaller-size vial, with the vial-coupling adaptor connected to the liquid-transfer device's vial-coupling end. Following a liquid-transfer operation with this smaller vial, the same is decoupled, and such decoupling automatically disconnects the vial-coupling adaptor and the liquid-transfer device.
Thereafter, a vial of the larger size is coupled to the vial-coupling end in the liquid-transfer device, and a transfer procedure is completed between the syringe and the larger coupled vial.
Thereafter, a vial of the larger size is coupled to the vial-coupling end in the liquid-transfer device, and a transfer procedure is completed between the syringe and the larger coupled vial.
Description
His 6"' MEDICATION VIAL/SYRINGE LIQUID-TRAhtSFER APPARATUS
Technical Field The present invention relates to liquid-transfer apparatus which is interposabIe a syringe and a medication vial for facilitating the passage of liquid therebetween during the preparation of a dispensible pharmaceutical.
Background and Summary of the Invention In the field of medicine, it is often the case that liquid pharmaceuticals must be prepared for delivery to a patient by a syringe. Such preparation typically involves the withdrawing into a syringe of a diluent liquid contained in a first vial, the subsequent injection of that liquid from the syringe into a second vial which contains a blendable, dissolvable medicine in powder form, and thereafter the withdrawal of the now-blended pharmaceutical medicine from that second vial back into the syringe. It is most frequently, though not always, the situation that the first vial from which diluent liquid is withdrawn is smaller (in mouth-opening-diameter size) than the second vial wherein blending occurs -- which second vial has a larger mouth-opening-diameter size. A
procedure falling within this category is referred to herein as involving first a smaller-size vial, and thereafter a larger-size vial. One should note that such references to smaller, and larger vial sizes are related to mouth-opening sizes, and not necessarily to vial volume sizes. In the balance of preparation situations, two vials of the same mouth-opening size are employed throughout the operation.
To aid in the practice of such back-and-forth transfer/delivery of liquid between a vial and a syringe, and to take into account safety and health concerns regarding, infer alia, contaminization, loss of sterilization, and exposure of medical personnel to injuries from sharps (such as hypodermic needles), prior work in this field has witnessed the creation and development of various liquid-transfer devices, or interfaces, which allow both for convenient coupling to a syringe and to a vial for liquid transfer, and for minimization of the several kinds of safety and health concerns just mentioned.
Two issues which are not well addressed by known prior art approaches to such liquid-transfer requirements are, first, that highly convenient accommodation of transfer apparatus to the handling of two different vial sizes has not been offered, and second, that a testy problem, referred to as "foaming", has not apparently been well addressed. Foaming is a bubbling action which can and does readily occur during that part of a liquid-transfer process wherein diluent is injected into a vial containing dissolvable powdered medicine. Foaming introduces problematic air bubbles which must be removed before any delivery to a patient.
Accordingly, it is desired to provide an improved form of liquid-transfer apparatus which offers all of the key advantages of known prior art devices aimed at this purpose, but which, in addition, avoids the drawbacks (i.e., the not well-addressed issues) mentioned above.
The invention provides an elongate, unitary liquid-transfer device operatively interposable between a syringe and a vial, and which is constructed for use with a vial of the type including a vessel with a mouth closed by a pierceable stopper, and where the stopper includes a hollow-interior, central, annular, projecting wall structure with an open end defining a cup with a base facing the interior of the vessel, said device comprising a syringe-coupling end, a vial-coupling end, and liquid-passage structure including an elongate channel extending axially centrally in said device from said syringe-coupling end toward said vial-coupling end, and at least one laterally facing port communicating with said channel adjacent said vial-coupling end, said liquid-passage structure, at the region of communication between said channel and said port, being constructed to limit liquid flow out of said port predominantly to generally radial flow relative to the length of said channel, said vial-coupling end being constructed whereby, with the device coupled to such a vial, said port is located within the stopper's cup and closely adjacent the cup's base.
The invention also provides liquid-transfer apparatus operatively interposable between a syringe and a vial, and accommodating sequential operative coupling first to the top of a vial having one size, and thereafter to the top of a vial having another, larger size, said apparatus comprising a liquid-transfer device including a syringe-coupling end, a vial-coupling end and liquid-passage structure effectively communicating between said ends, said vial-coupling end being sized for direct coupling to the top of a vial having such other, larger size, and a vial-coupling adaptor removably receivable in a connected relationship with said vial-coupling end to adapt the same for coupling of the apparatus to the top of a vial having such smaller, one size.
2a The invention further provides a method of transferring liquid between a syringe and a vial, where the vial is of the type including a pierceable stopper having an inwardly facing cup with an inwardly facing base, said method comprising utilizing a transfer device which includes a syringe-coupling end, a vial-coupling end, and liquid-passage structure communicating therebetween and including at least one laterally-facing port open adjacent the vial-coupling end, coupling a selected syringe and a selected vial to such respective ends, and by said coupling action, as such relates to the selected vial, piercing the vial's stopper and establishing a coupled condition with the vial wherein the mentioned port in the liquid-passage structure is positioned within the vial's stopper's cup, closely adjacent the cup's base.
The invention further provides a method of transferring liquid between a syringe and a vial under circumstances that require accommodating sequential operative coupling first to the top of the vial having one size, and thereafter to the top of a vial having another larger size, said method comprising utilizing liquid-transfer apparatus which includes a liquid-transfer device including a syringe-coupling end, a vial-coupling end sized to receive directly the top of a vial having such other, larger size, and liquid-passage structure communicating between these ends, and a vial-coupling adaptor removably receivable in a connected relationship with the mentioned vial-coupling end to adapt the same 2b for coupling of the apparatus to the top of a vial having such smaller, one size, establishing a connected relationship between the liquid-transfer device and the vial-coupling adaptor, coupling a selected syringe and a selected vial having such smaller, one size, performing a liquid-transfer operation between the selected syringe and the selected vial, decoupling the first selected vial, and by said decoupling automatically disconnecting the vial-coupling adaptor and the liquid-transfer device, selecting a second vial of the type characterized by such other, larger size and coupling the same to the vial-coupling end in the liquid-transfer device, and performing at least one other liquid-transfer operation.
The disclosed apparatus readily and easily accommodates transfers back and forth of liquid between a syringe and vials of the same size, as well as such transfers between a syringe and vials of two different sizes.
The transfer apparatus which uniquely creates an "ejection"
liquid-flow into a vial that contains dissolvable powdered medicine in a fashion that greatly minimizes, and in very many instances completely avoids, the problem mentioned above known as foaming.
The apparatus includes a ported spike which pierces and extends through the usual elastomeric stopper found in a vial, and, further, is constructed in such a manner that with the 2c spike piercing a conventional stopper, ports in the spike are contained within the usually present inwardly facing "cup" in the stopper, and in particular, in a condition closely adjacent the base in the cup. This ensures a situation wherein it is possible, predictably, and with no special effort required, and during withdrawing of liquid from a vial, to gather substantially all of the liquid in that vial.
Considering what we view to be the preferred organization of the present invention, that organization takes fi,mdamentally two different forms. In one form, which form is desired to deal with the situation where only vials of the same size are ever used, the apparatus of the invention employs but a single unit, which we refer to as a liquid-transfer device. This device has a syringe-coupling end, a vial-coupling end which is sized to accommodate coupling to the particular single vial size that will be encountered, and special liquid passage structure which e;~tends effectively for communication between the two mentioned ends of the device. The second organizational form of the invention is aimed at addressing, inter alia, the situation where two different sizes of vials need to be coupled-to during a preparation operation. In this form of the invention, two components are employed. One of these is a liquid-transfer device of the kind just mentioned above, with this transfer device being sized, at its vial-coupling end, to accommodate coupling to the larger size of the two vials which will be addressed. The other component takes the form of a slider/adaptor that fits in a connected (such as nested), removable relationship with respect to the vial-coupling end in the transfer device to accommodate direct coupling to a vial of the smaller of the two vial sizes which will be addressed.
wth respect to both of these two forms of the invention, when an appropriate vial (of arty size) is coupled-to for a liquid-transfer operation, and under circumstances where liquid is being -, ~ ~:~~ °~~
injected through the transfer device into an attached vial, the liquid passage structure mentioned above directs liquid flow into the vial via a pair of tiny, laterally facing ports which reside, relatively positionally, within the hollow interior of an annular projection formed in the vial's stopper, which hollow interior faces the interior of the vial. This conventional annular projection and hollow interior thereof define what is referred to herein as a cup that faces (axially) the interior of the associated vial, and the port in the apparatus of the invention is located within the interior of this cup and closely adjacent the base of the cup. With this relationship extant -- a relationship which exists because of certain special constructional features proposed according to the invention --and with the two ports organized as generally described, liquid flow into a vial is predominantly generally radial in nature, and IO uniquely suited to creating major liquid :low into the vial down the inside wall of the vial to minimize foaming.
Another feature of this kind of relationship which exists between the ports of the invention and the stopper's cup under circumstances where liquid is being withdrawn from a vial is that, with appropriate inversion of a val, substantially all of liquid content can easily be withdrawn.
These and other objects, features and advantages which are offered by the present invention will become more fully apparent as the description that now follows is read in conjunction with the accompanying drawings.
Description of the Drawings Fig. I is a side elevation of apparatus constructed in accordance with the present 20 invention, displayed horizontally alongside a conventional syringe with respect to which it is intended for use. The apparatus of the invention (pictured in cross section in the figure) includes two elements (shown separated), both of which are employed according to ~ one organization of the invention ~~ ~ ~ ~~~ =w .
designed to handle two different sizes of vials, and one only of which is employed according to another organization of the invention wherein only a single-size vial is involved.
Fig. 2 is a view, on a larger scale than that employed in Fib. 1, of the two invention components pictured in Fib. 1.
Fig. 2A is an enlarged, fragmentary detail taken generally along line 2 A-2A
in Fig. ?.
Fig. 3 is a view on about the same scale as that used in Fig. 2, illustrating the two "separated" components of Fig. 2 assembled horizontally in such a fashion that the left-hand component in the figure is slidably nested within structure That forms part of the right-hand component in the figure.
Fig. 4 is a side view, partly in cross section, illustrating what is referred to herein as a smaller-size vial, with this vial displayed in a vertical or upright condition.
Fig. 5 is an upright side view, partly in cross section, of what is referred to herein as a larger-size vial.
Fig. 6 snows the apparatus and syringe of Fig. 1 in fially-assembled form in a condition of readiness to begin a pharmaceutical preparation operation involving the sequential coupling to two different vial sizes, beginning with coupling to a smaller vial size, and ending with coupling to a lamer vial size, as will shortly be explained.
Figs. 7-14, inclusive, illustrate stages in the use of the apparatus of this invention to perform a liquid pharmaceutical preparation of the most commonly encountered type which requires sequential coupling to two different sizes of vials, commencing with the smaller one of these two sizes.
Various features illustrated in the drawings, though close to, are not necessarily depicted in enact scale and/or proportion.
Detailed Description of, and Best Mode for Carrvina Out, the invention Turning attention now to the drawings, and referring first of ail to Figs. 1 and 2, indicated generally at 20, in non-attached, non-coupled condition, is liquid-transfer apparatus constructed in accordance with the present invention. This apparatus is intended for use, as will be explained, with a conventional syringe, such as the syringe shown in Fig. 1 at 22. Apparatus 20 irciudes what we refer to herein as a liquid-transfer device 24, and a vial-coupling adaptor 26. In the most commonly used form of the invention, both device ?4 and adaptor 26 are employed. In a somewhat less common application, only device 24 is employed. Initially, the description of the invention herein will proceed with the view that both device 24 and adaptor 26 are used. Following that description will come a description of how the invention is employed utilizing only device 24.
Syringe 22 which, as has been mentioned, is a conventional syringe, includes a body 22a having a communication end 22b which is, in the specinc style of syringe illustrated, threaded for a so-called (and well-known) Luer-type screw connection, and an elongate plunger 22c. While syringe 22 is described and illustrated herein in conjunction with having a Luer-type screw connection at its communication end, it could just as well be formed with what is known as a Luer-type tapered compression (non-screw) connection at that end, or, in fact, with any other type of appropriate connection.
Focussing attention now on the details of construction of the two invention components illustrated; transfer device 24, which preferably is formed of a suitable molded thermoplastic material, includes a syringe-coupling end 24a that joins unitarily with a vial-coupling end 24b. _End 24a is constructed, as illustrated herein, with threading projection structure 24c which accommodates a screw connection with communication end 22b of syringe 22. It should be understood, of course, that end 24a can be constructed accordingly to accommodate connection with syringes having various other styles of communication ends. Device 24 is, in large part, a body of revolution which is centered on and about a longitudinal axis shown at 28.
End 24b is formed with a central vial-stopper-piercing spike 24d which is symmetrically circumsurrounded by an annular shroud/collar .4e, on the inside cylindrical wall of which are formed plural, distributed, slightly domed protuberances, such as protuberance 24_f. These protuberances, of which there are six, equiangularly distributed, are disposed close to the left open face of end 24b in Figs. 1 and 2. As will be explained later, they function as a vial-grip structure.
Extending axially centrally into end 24a, and partially into end 24b via spike 24d, is what can be thought of as, generally, a stepped-diameter central channel 24g.
The right end of channel 24g in Figs. l and 2 is open along axis 28, whereas the left end of this channel in these figures is barriered across axis 28 by a generally planar barrier wall ?4h. Wall 24h extends in a plane which is substantially normal to axis 28.
Considering now Fig. 2A along with Fias. 1 and 2, communicating with the left end of channel 24g in Figs. 1 and 2 are two, generally rectangular, laterally-facing ports 24i. Focusing attention especially on Fig. 2A, each of ports 24i has a width, measured as indicated by the letter W, lying within the range of about 0.02- to about 0.03-inches, and preferably toward the lower end of this range. The length of each port, indicated by L, preferably lies within the range of about 0.02- to about 0.03-inches. Dimensions W and L, referred to herein as transverse dimensions, and as seen in Fig. 2A, mark the lateral boundaries of what is referred to herein as an exit profile for the port which has an area lying within the range of about 0.0004-in2 to about 0.0009-in'', and preferably witty an area toward the lower end of this range. In the particular embodiment now being described dimension W is slightly >~i~ ~,, ~-~
!~ =ho , war smaller than dimension L. Barrier wall 24h is refer, ed to herein as at least partially defining a region of communication between channel 24g and ports 24i. The channel and ports are referred to collectively herein as a liquid-passage structure.
In relation to the delivery of liquid through device 24 from end 24a toward end 24b, end 24a is referred to as the upstream end of the device, and end 24b as the downstream end. Such liquid delivery results in ejection of liquid from ports 24i which is limited predominantly to generally radial flow relative to long axis 28.
Continuing a description of device 24, and in the context of the apparatus of the invention being used in conjunction with two different sizes of vials, the inside of shroud/coilar 24e is sized to receive, directly and moderately snugly, the banded mouth end (top) of the larger one of the two vial sizes involved. In particular, it is adapted to receive this vial end in such a fashion that what we refer to as the underside shoulder of the band in the vial is borne against, and grripped in place, by protuberances 24_f. This condition is clearly illustrated in, and will be mentioned again in conjunction with, anotrer drawing figure still to be discussed. A special feature to note at this point is that, effectively, protuberances 24f are located downstream from ports 24i relative to channel 24g. It is this relationship which results in important positioning of ports 24i within the cup of the typical vial stopper -- a condition also still to be described in relation with a yet-to-be-discussed, other drawing figure.
Adaptor 26 is preferably formed of a suitable molded thermoplastic material.
It includes an outer cylindrical skirt portion, or skirt, 26a, extending inwardly from the left end of which in Figs. 1 and 2 are plural, conicallv converging spring fingers, such as those shown at 26b. Extending circumferentially around the outside of skirt 26a at an appropriate location axially therealong, which location will be discussed more fully shortly, is a shallow ~oove 26c. The left side or end of adaptor 26 in Figs. 1 and 2 is referred to herein as its vial-facing end.
6.~ Tt P':
Considering Fig. 3, now along with Figs. 1 and 2, adaptor 26 is intended to coact with transfer device 24 to adapt the same for dealing with the smaller-size vial that is employed in a two-size, two-vial preparation operation. At the beginning of such an operation, adaptor 26 is inserted slidably into shroud/collar 24e to the received position indicated in Fig. 3.
In this received position, protuberances 24f snap, in a detent-like way, into groove 26c, thus to tend to retain device 24 and adaptor 26 in a fit-together connected condition. The particular connected condition, or relationship, illustrated in Fig. 3 is one that we refer to as a "nested" condition. Other fit-together, connected conditions could, of course, be used.
During operation of the apparatus of the invention with the mentioned smaller-size vial, when the top of that vial is coupled to the apparatus, the underside shoulder of the band surrounding the mouth in that vial is borne against, and gripped by, the inner free ends of fingers 26b in adaptor 26.
These fingers, therefore, are referred to also herein as vial-grip structure.
Looking especially at what is illustrated in Fig. 3, in the embodiment of the invention now being described, with device 24 and adaptor 26 in the relative positions indicated in Fig. 3, one can see that the free ends of the fingers are located "downstream" from ports 24i.
Fig. 4 illustrates at ~0 what is referred to herein as a smaller-size vial, and Fig. ~
illustrates at 32 what is referred to herein as a larder-size vial. The most commonly used vial sizes today in the field of medicine are referred to as 13-mm vials and 20-mm vials, and accordingly, the apparatus of the invention now being described is specifically sized to handle these two sizes of vials.
These two discussions are vial mouth diameter dimensions. It should be evident to those skilled in the art that the apparatus could be sized to handle other specific vial sizes if so desired.
Vial 30 includes a vessel 34 with a mouth 34a which is closed off by an elastomeric stopper 36 that is held in sealing relationship with mouth 34a by an annular band, typically a metallic band, 38 which has what we refer to herein as an underside shoulder 38a. The upper central surface of stopper 36 is exposed for piercing to gain access to the interior of the vessel, and the underside of this stopper, as pictured in Fig. 4, includes a hollow-interior, central, annular projecting wall structure 36a which has an open end (the lower end in Fig. 4) facing, axially, the interior of vessel 34. This open end defines in stopper 36 a cup 36b that has a downwardly facing base 36c. In a two-size, two-vial procedure, the smaller-size vial, like vial 30, contains an appropriate liquid diluent.
wth the exception of the fact that vial 32 is larger than vial 34, vial 32 is, generically in other respects, substantially the same as vial 30. Thus, vial 32 includes a vessel 40 with a mouth 40a which is closed by an elastomeric stopper 42 that is held in sealing relationship with the vessel by an annular band 44 which has an underside shoulder 44a. Stopper 42 includes a wall structure 42a which is somewhat like previously-mentioned wall structure 36a, and a cup 42b which is somewhat like previously-mentioned cup 36b. Cup 42b has a downwardly facing base 42c.
In a two-size, two-vial procedure, the larger-size vial, like vial 32, contains, at least initially, powdered medicine which is dissolvable in and by the diluent contained in the smaller-size vial.
Having thus now described the constituent elements of the apparatus of the present invention, and the external structures (syringe and vials) with respect to which the invention is intended for use, let us now launch into a typical two-size, two-vial liquid pharmaceutical preparation procedure.
As was mentioned earlier, Fig. 6 in the drawings illustrates the beginning of the procedure wherein device 24 and adaptor 26 are fit together, and the communication end of syringe 22 is coupled to syringe-coupling end 24a in device 24.
This assemblage is then confronted with the mouth end of a diluent-containing, smailer-size vial, like vial 30, and as pictured in Fig. 7, these two separated elements are driven toward one another until the vial is fully coupled to the transfer apparatus -- a condition illustrated in Fig. 3. The ' 1 r l'r, ,, ,r ~j L~ ~!
conical organization of fingers 26b tends to guide and direct the vial centrally into vial-coupling end 24b_, and into a condition with spike 24d centrally piercing the stopper in the vial. The inner ends of fingers 26b bear against the underside shoulder of the band in the vial, and tend to hold the vial in place against involuntary ejection under the now-present influence of the deflected central portion of the vial's stopper.
Focusing attention on Fig. 9 which, as has been mentioned, is an enlarged detail derived from Fig. 8, one can see the central deflection which exists in the stopper, and that ports 24i are received well within the stopper's cup in the stopper in the vial, and closely adjacent the base of the cup.
Preferably, now, by up-ending tl'~is filly connected organization so that vial 30 is inverted, the plunger in the syringe is withdrawn, as indicated by the arrow in Fig. 8, to draw liquid diluent from the vial into the body of the syringe. The fact that ports 24i are well within the cup in the stopper, and closely adjacent the base of the cup, results in substantial assurance that essentially all of the liquid in the vial will be gathered.
Ne,~ct, the now-emptied small vial is withdrawn by pulling it to the left away from the coupled syringe, as indicated in Fig. 10, with such withdrawal action automatically causing adaptor 26 to separate from device 24 and to remain attached to the smaller vial. Such convenient, automatic separation of adaptor 26 and device 24 is an advantageous feature of the apparatus of the invention.
Next, and looking now at Fig. 11, the mouth end of a larger-size vial, such as vial 32, is directed as indicated toward vial-coupling end 24b, with the portion of shroud/collar 24e which extends longitudinally beyond spike 26d tending to gather, guide and centralize the mouth end of the vial relative to spike 24d. This action results in full coupling of the larder vial with device 24, as indicated in Fig. 12. Under these circumstances, and now referring to Fig. 13, along with Fig. 12, one ~~ ~~"°~
can see that the underside shoulder of the band in vial 32 is borne against and therefore gripped by protuberances 24~ and that ports 24i are positioned within the cup in the vial's stopper closely adjacent the base of that cup. Protuberances 24f tend to hold this larger vial in place against the same land of involuntary ejection mentioned earlier -- such ejection being promoted under the influence of central deflection in the stopper, which deflection is clearly evident in Fig. 13.
The plunger in the syringe is then moved as indicated by the double-ended arrow in Fig. 12, first inwardly into the body of the syringe to eject diluent liquid into vial 32 for the purpose of mixing and blending with the dry powdered medicine initially resident in vial 32, and after mixing, then outwardly from the body of the syringe to extract fully-blended pharmaceutical liquid.
With the construction of the apparatus of the invention as described, and considering the construction of the liquid-passage structure, liquid ejected into vial 32 exits ports 24i substantially radially against the adjacent surfaces of the stopper cup, and this action tends to cause liquid entering the vial to flow outwardly and downwardly along the inside wall of the vessel in the vial so as to minimize unwanted foaming. Ordinarily, this ejection activity takes place with the vial generally upright, or at least at some upwardly inclined angle. Withdrawing of blended material from vial 32 is typically accomplished by inverting the coupled assemblage so that substantially all of the blended material in the vial ultimately gathers near the base of the stopper's cup where it is readily accessible for extraction through into ports 24i.
With the syringe now filled with a fully-prepared dispensible liquid pharmaceutical, the syringe is decoupled from device 24 as indicated by Fig. 14.
In modern practice, the constituent elements of the apparatus of the invention are not re-used, and so remain with the now-spent vials with which they are discharged.
_ ~ i;, Reviewing very briefly an aspect of the procedure which has just been described, one should note that, because of the positional relationship which exists in each case where a vial is fully coupled for liquid transfer, the acting vial-grip structure is positioned relative to ports 24i in such a manner that the ports become properly positioned witrin the associated stopper cup.
Under circumstances where the apparatus of the invention is intended to be used in a single-size, two-vial procedure, only a device like liquid-transfer device 24 needs to be employed. The manner of practicing this procedure should be clear from the description which has just been given above, recognizing that decoupling of the first-used val in the procedure is done without removing device 24 from the communication end of a coupled syringe.
Accordingly, the apparatus of the invention clearly meets the objectives and offer s the advantages ascribed to it earlier herein. For example, it affords ready accommodation both of same-vial-sizes and of different-vial-sizes in a very easy manner. Foaming problems are greatly minimized, if not all together avoided. Gathering and withdrawing of liquid from a vial is facilitated by the close positioning which exists between the ports in the apparatus of the invention and the base of a cup in the stopper of a coupled vial.
While a preferred structural form of the invention has been described and illustrated herein, we appreciate that certain variations and modifications may be made without departing from the spirit of the invention.
Technical Field The present invention relates to liquid-transfer apparatus which is interposabIe a syringe and a medication vial for facilitating the passage of liquid therebetween during the preparation of a dispensible pharmaceutical.
Background and Summary of the Invention In the field of medicine, it is often the case that liquid pharmaceuticals must be prepared for delivery to a patient by a syringe. Such preparation typically involves the withdrawing into a syringe of a diluent liquid contained in a first vial, the subsequent injection of that liquid from the syringe into a second vial which contains a blendable, dissolvable medicine in powder form, and thereafter the withdrawal of the now-blended pharmaceutical medicine from that second vial back into the syringe. It is most frequently, though not always, the situation that the first vial from which diluent liquid is withdrawn is smaller (in mouth-opening-diameter size) than the second vial wherein blending occurs -- which second vial has a larger mouth-opening-diameter size. A
procedure falling within this category is referred to herein as involving first a smaller-size vial, and thereafter a larger-size vial. One should note that such references to smaller, and larger vial sizes are related to mouth-opening sizes, and not necessarily to vial volume sizes. In the balance of preparation situations, two vials of the same mouth-opening size are employed throughout the operation.
To aid in the practice of such back-and-forth transfer/delivery of liquid between a vial and a syringe, and to take into account safety and health concerns regarding, infer alia, contaminization, loss of sterilization, and exposure of medical personnel to injuries from sharps (such as hypodermic needles), prior work in this field has witnessed the creation and development of various liquid-transfer devices, or interfaces, which allow both for convenient coupling to a syringe and to a vial for liquid transfer, and for minimization of the several kinds of safety and health concerns just mentioned.
Two issues which are not well addressed by known prior art approaches to such liquid-transfer requirements are, first, that highly convenient accommodation of transfer apparatus to the handling of two different vial sizes has not been offered, and second, that a testy problem, referred to as "foaming", has not apparently been well addressed. Foaming is a bubbling action which can and does readily occur during that part of a liquid-transfer process wherein diluent is injected into a vial containing dissolvable powdered medicine. Foaming introduces problematic air bubbles which must be removed before any delivery to a patient.
Accordingly, it is desired to provide an improved form of liquid-transfer apparatus which offers all of the key advantages of known prior art devices aimed at this purpose, but which, in addition, avoids the drawbacks (i.e., the not well-addressed issues) mentioned above.
The invention provides an elongate, unitary liquid-transfer device operatively interposable between a syringe and a vial, and which is constructed for use with a vial of the type including a vessel with a mouth closed by a pierceable stopper, and where the stopper includes a hollow-interior, central, annular, projecting wall structure with an open end defining a cup with a base facing the interior of the vessel, said device comprising a syringe-coupling end, a vial-coupling end, and liquid-passage structure including an elongate channel extending axially centrally in said device from said syringe-coupling end toward said vial-coupling end, and at least one laterally facing port communicating with said channel adjacent said vial-coupling end, said liquid-passage structure, at the region of communication between said channel and said port, being constructed to limit liquid flow out of said port predominantly to generally radial flow relative to the length of said channel, said vial-coupling end being constructed whereby, with the device coupled to such a vial, said port is located within the stopper's cup and closely adjacent the cup's base.
The invention also provides liquid-transfer apparatus operatively interposable between a syringe and a vial, and accommodating sequential operative coupling first to the top of a vial having one size, and thereafter to the top of a vial having another, larger size, said apparatus comprising a liquid-transfer device including a syringe-coupling end, a vial-coupling end and liquid-passage structure effectively communicating between said ends, said vial-coupling end being sized for direct coupling to the top of a vial having such other, larger size, and a vial-coupling adaptor removably receivable in a connected relationship with said vial-coupling end to adapt the same for coupling of the apparatus to the top of a vial having such smaller, one size.
2a The invention further provides a method of transferring liquid between a syringe and a vial, where the vial is of the type including a pierceable stopper having an inwardly facing cup with an inwardly facing base, said method comprising utilizing a transfer device which includes a syringe-coupling end, a vial-coupling end, and liquid-passage structure communicating therebetween and including at least one laterally-facing port open adjacent the vial-coupling end, coupling a selected syringe and a selected vial to such respective ends, and by said coupling action, as such relates to the selected vial, piercing the vial's stopper and establishing a coupled condition with the vial wherein the mentioned port in the liquid-passage structure is positioned within the vial's stopper's cup, closely adjacent the cup's base.
The invention further provides a method of transferring liquid between a syringe and a vial under circumstances that require accommodating sequential operative coupling first to the top of the vial having one size, and thereafter to the top of a vial having another larger size, said method comprising utilizing liquid-transfer apparatus which includes a liquid-transfer device including a syringe-coupling end, a vial-coupling end sized to receive directly the top of a vial having such other, larger size, and liquid-passage structure communicating between these ends, and a vial-coupling adaptor removably receivable in a connected relationship with the mentioned vial-coupling end to adapt the same 2b for coupling of the apparatus to the top of a vial having such smaller, one size, establishing a connected relationship between the liquid-transfer device and the vial-coupling adaptor, coupling a selected syringe and a selected vial having such smaller, one size, performing a liquid-transfer operation between the selected syringe and the selected vial, decoupling the first selected vial, and by said decoupling automatically disconnecting the vial-coupling adaptor and the liquid-transfer device, selecting a second vial of the type characterized by such other, larger size and coupling the same to the vial-coupling end in the liquid-transfer device, and performing at least one other liquid-transfer operation.
The disclosed apparatus readily and easily accommodates transfers back and forth of liquid between a syringe and vials of the same size, as well as such transfers between a syringe and vials of two different sizes.
The transfer apparatus which uniquely creates an "ejection"
liquid-flow into a vial that contains dissolvable powdered medicine in a fashion that greatly minimizes, and in very many instances completely avoids, the problem mentioned above known as foaming.
The apparatus includes a ported spike which pierces and extends through the usual elastomeric stopper found in a vial, and, further, is constructed in such a manner that with the 2c spike piercing a conventional stopper, ports in the spike are contained within the usually present inwardly facing "cup" in the stopper, and in particular, in a condition closely adjacent the base in the cup. This ensures a situation wherein it is possible, predictably, and with no special effort required, and during withdrawing of liquid from a vial, to gather substantially all of the liquid in that vial.
Considering what we view to be the preferred organization of the present invention, that organization takes fi,mdamentally two different forms. In one form, which form is desired to deal with the situation where only vials of the same size are ever used, the apparatus of the invention employs but a single unit, which we refer to as a liquid-transfer device. This device has a syringe-coupling end, a vial-coupling end which is sized to accommodate coupling to the particular single vial size that will be encountered, and special liquid passage structure which e;~tends effectively for communication between the two mentioned ends of the device. The second organizational form of the invention is aimed at addressing, inter alia, the situation where two different sizes of vials need to be coupled-to during a preparation operation. In this form of the invention, two components are employed. One of these is a liquid-transfer device of the kind just mentioned above, with this transfer device being sized, at its vial-coupling end, to accommodate coupling to the larger size of the two vials which will be addressed. The other component takes the form of a slider/adaptor that fits in a connected (such as nested), removable relationship with respect to the vial-coupling end in the transfer device to accommodate direct coupling to a vial of the smaller of the two vial sizes which will be addressed.
wth respect to both of these two forms of the invention, when an appropriate vial (of arty size) is coupled-to for a liquid-transfer operation, and under circumstances where liquid is being -, ~ ~:~~ °~~
injected through the transfer device into an attached vial, the liquid passage structure mentioned above directs liquid flow into the vial via a pair of tiny, laterally facing ports which reside, relatively positionally, within the hollow interior of an annular projection formed in the vial's stopper, which hollow interior faces the interior of the vial. This conventional annular projection and hollow interior thereof define what is referred to herein as a cup that faces (axially) the interior of the associated vial, and the port in the apparatus of the invention is located within the interior of this cup and closely adjacent the base of the cup. With this relationship extant -- a relationship which exists because of certain special constructional features proposed according to the invention --and with the two ports organized as generally described, liquid flow into a vial is predominantly generally radial in nature, and IO uniquely suited to creating major liquid :low into the vial down the inside wall of the vial to minimize foaming.
Another feature of this kind of relationship which exists between the ports of the invention and the stopper's cup under circumstances where liquid is being withdrawn from a vial is that, with appropriate inversion of a val, substantially all of liquid content can easily be withdrawn.
These and other objects, features and advantages which are offered by the present invention will become more fully apparent as the description that now follows is read in conjunction with the accompanying drawings.
Description of the Drawings Fig. I is a side elevation of apparatus constructed in accordance with the present 20 invention, displayed horizontally alongside a conventional syringe with respect to which it is intended for use. The apparatus of the invention (pictured in cross section in the figure) includes two elements (shown separated), both of which are employed according to ~ one organization of the invention ~~ ~ ~ ~~~ =w .
designed to handle two different sizes of vials, and one only of which is employed according to another organization of the invention wherein only a single-size vial is involved.
Fig. 2 is a view, on a larger scale than that employed in Fib. 1, of the two invention components pictured in Fib. 1.
Fig. 2A is an enlarged, fragmentary detail taken generally along line 2 A-2A
in Fig. ?.
Fig. 3 is a view on about the same scale as that used in Fig. 2, illustrating the two "separated" components of Fig. 2 assembled horizontally in such a fashion that the left-hand component in the figure is slidably nested within structure That forms part of the right-hand component in the figure.
Fig. 4 is a side view, partly in cross section, illustrating what is referred to herein as a smaller-size vial, with this vial displayed in a vertical or upright condition.
Fig. 5 is an upright side view, partly in cross section, of what is referred to herein as a larger-size vial.
Fig. 6 snows the apparatus and syringe of Fig. 1 in fially-assembled form in a condition of readiness to begin a pharmaceutical preparation operation involving the sequential coupling to two different vial sizes, beginning with coupling to a smaller vial size, and ending with coupling to a lamer vial size, as will shortly be explained.
Figs. 7-14, inclusive, illustrate stages in the use of the apparatus of this invention to perform a liquid pharmaceutical preparation of the most commonly encountered type which requires sequential coupling to two different sizes of vials, commencing with the smaller one of these two sizes.
Various features illustrated in the drawings, though close to, are not necessarily depicted in enact scale and/or proportion.
Detailed Description of, and Best Mode for Carrvina Out, the invention Turning attention now to the drawings, and referring first of ail to Figs. 1 and 2, indicated generally at 20, in non-attached, non-coupled condition, is liquid-transfer apparatus constructed in accordance with the present invention. This apparatus is intended for use, as will be explained, with a conventional syringe, such as the syringe shown in Fig. 1 at 22. Apparatus 20 irciudes what we refer to herein as a liquid-transfer device 24, and a vial-coupling adaptor 26. In the most commonly used form of the invention, both device ?4 and adaptor 26 are employed. In a somewhat less common application, only device 24 is employed. Initially, the description of the invention herein will proceed with the view that both device 24 and adaptor 26 are used. Following that description will come a description of how the invention is employed utilizing only device 24.
Syringe 22 which, as has been mentioned, is a conventional syringe, includes a body 22a having a communication end 22b which is, in the specinc style of syringe illustrated, threaded for a so-called (and well-known) Luer-type screw connection, and an elongate plunger 22c. While syringe 22 is described and illustrated herein in conjunction with having a Luer-type screw connection at its communication end, it could just as well be formed with what is known as a Luer-type tapered compression (non-screw) connection at that end, or, in fact, with any other type of appropriate connection.
Focussing attention now on the details of construction of the two invention components illustrated; transfer device 24, which preferably is formed of a suitable molded thermoplastic material, includes a syringe-coupling end 24a that joins unitarily with a vial-coupling end 24b. _End 24a is constructed, as illustrated herein, with threading projection structure 24c which accommodates a screw connection with communication end 22b of syringe 22. It should be understood, of course, that end 24a can be constructed accordingly to accommodate connection with syringes having various other styles of communication ends. Device 24 is, in large part, a body of revolution which is centered on and about a longitudinal axis shown at 28.
End 24b is formed with a central vial-stopper-piercing spike 24d which is symmetrically circumsurrounded by an annular shroud/collar .4e, on the inside cylindrical wall of which are formed plural, distributed, slightly domed protuberances, such as protuberance 24_f. These protuberances, of which there are six, equiangularly distributed, are disposed close to the left open face of end 24b in Figs. 1 and 2. As will be explained later, they function as a vial-grip structure.
Extending axially centrally into end 24a, and partially into end 24b via spike 24d, is what can be thought of as, generally, a stepped-diameter central channel 24g.
The right end of channel 24g in Figs. l and 2 is open along axis 28, whereas the left end of this channel in these figures is barriered across axis 28 by a generally planar barrier wall ?4h. Wall 24h extends in a plane which is substantially normal to axis 28.
Considering now Fig. 2A along with Fias. 1 and 2, communicating with the left end of channel 24g in Figs. 1 and 2 are two, generally rectangular, laterally-facing ports 24i. Focusing attention especially on Fig. 2A, each of ports 24i has a width, measured as indicated by the letter W, lying within the range of about 0.02- to about 0.03-inches, and preferably toward the lower end of this range. The length of each port, indicated by L, preferably lies within the range of about 0.02- to about 0.03-inches. Dimensions W and L, referred to herein as transverse dimensions, and as seen in Fig. 2A, mark the lateral boundaries of what is referred to herein as an exit profile for the port which has an area lying within the range of about 0.0004-in2 to about 0.0009-in'', and preferably witty an area toward the lower end of this range. In the particular embodiment now being described dimension W is slightly >~i~ ~,, ~-~
!~ =ho , war smaller than dimension L. Barrier wall 24h is refer, ed to herein as at least partially defining a region of communication between channel 24g and ports 24i. The channel and ports are referred to collectively herein as a liquid-passage structure.
In relation to the delivery of liquid through device 24 from end 24a toward end 24b, end 24a is referred to as the upstream end of the device, and end 24b as the downstream end. Such liquid delivery results in ejection of liquid from ports 24i which is limited predominantly to generally radial flow relative to long axis 28.
Continuing a description of device 24, and in the context of the apparatus of the invention being used in conjunction with two different sizes of vials, the inside of shroud/coilar 24e is sized to receive, directly and moderately snugly, the banded mouth end (top) of the larger one of the two vial sizes involved. In particular, it is adapted to receive this vial end in such a fashion that what we refer to as the underside shoulder of the band in the vial is borne against, and grripped in place, by protuberances 24_f. This condition is clearly illustrated in, and will be mentioned again in conjunction with, anotrer drawing figure still to be discussed. A special feature to note at this point is that, effectively, protuberances 24f are located downstream from ports 24i relative to channel 24g. It is this relationship which results in important positioning of ports 24i within the cup of the typical vial stopper -- a condition also still to be described in relation with a yet-to-be-discussed, other drawing figure.
Adaptor 26 is preferably formed of a suitable molded thermoplastic material.
It includes an outer cylindrical skirt portion, or skirt, 26a, extending inwardly from the left end of which in Figs. 1 and 2 are plural, conicallv converging spring fingers, such as those shown at 26b. Extending circumferentially around the outside of skirt 26a at an appropriate location axially therealong, which location will be discussed more fully shortly, is a shallow ~oove 26c. The left side or end of adaptor 26 in Figs. 1 and 2 is referred to herein as its vial-facing end.
6.~ Tt P':
Considering Fig. 3, now along with Figs. 1 and 2, adaptor 26 is intended to coact with transfer device 24 to adapt the same for dealing with the smaller-size vial that is employed in a two-size, two-vial preparation operation. At the beginning of such an operation, adaptor 26 is inserted slidably into shroud/collar 24e to the received position indicated in Fig. 3.
In this received position, protuberances 24f snap, in a detent-like way, into groove 26c, thus to tend to retain device 24 and adaptor 26 in a fit-together connected condition. The particular connected condition, or relationship, illustrated in Fig. 3 is one that we refer to as a "nested" condition. Other fit-together, connected conditions could, of course, be used.
During operation of the apparatus of the invention with the mentioned smaller-size vial, when the top of that vial is coupled to the apparatus, the underside shoulder of the band surrounding the mouth in that vial is borne against, and gripped by, the inner free ends of fingers 26b in adaptor 26.
These fingers, therefore, are referred to also herein as vial-grip structure.
Looking especially at what is illustrated in Fig. 3, in the embodiment of the invention now being described, with device 24 and adaptor 26 in the relative positions indicated in Fig. 3, one can see that the free ends of the fingers are located "downstream" from ports 24i.
Fig. 4 illustrates at ~0 what is referred to herein as a smaller-size vial, and Fig. ~
illustrates at 32 what is referred to herein as a larder-size vial. The most commonly used vial sizes today in the field of medicine are referred to as 13-mm vials and 20-mm vials, and accordingly, the apparatus of the invention now being described is specifically sized to handle these two sizes of vials.
These two discussions are vial mouth diameter dimensions. It should be evident to those skilled in the art that the apparatus could be sized to handle other specific vial sizes if so desired.
Vial 30 includes a vessel 34 with a mouth 34a which is closed off by an elastomeric stopper 36 that is held in sealing relationship with mouth 34a by an annular band, typically a metallic band, 38 which has what we refer to herein as an underside shoulder 38a. The upper central surface of stopper 36 is exposed for piercing to gain access to the interior of the vessel, and the underside of this stopper, as pictured in Fig. 4, includes a hollow-interior, central, annular projecting wall structure 36a which has an open end (the lower end in Fig. 4) facing, axially, the interior of vessel 34. This open end defines in stopper 36 a cup 36b that has a downwardly facing base 36c. In a two-size, two-vial procedure, the smaller-size vial, like vial 30, contains an appropriate liquid diluent.
wth the exception of the fact that vial 32 is larger than vial 34, vial 32 is, generically in other respects, substantially the same as vial 30. Thus, vial 32 includes a vessel 40 with a mouth 40a which is closed by an elastomeric stopper 42 that is held in sealing relationship with the vessel by an annular band 44 which has an underside shoulder 44a. Stopper 42 includes a wall structure 42a which is somewhat like previously-mentioned wall structure 36a, and a cup 42b which is somewhat like previously-mentioned cup 36b. Cup 42b has a downwardly facing base 42c.
In a two-size, two-vial procedure, the larger-size vial, like vial 32, contains, at least initially, powdered medicine which is dissolvable in and by the diluent contained in the smaller-size vial.
Having thus now described the constituent elements of the apparatus of the present invention, and the external structures (syringe and vials) with respect to which the invention is intended for use, let us now launch into a typical two-size, two-vial liquid pharmaceutical preparation procedure.
As was mentioned earlier, Fig. 6 in the drawings illustrates the beginning of the procedure wherein device 24 and adaptor 26 are fit together, and the communication end of syringe 22 is coupled to syringe-coupling end 24a in device 24.
This assemblage is then confronted with the mouth end of a diluent-containing, smailer-size vial, like vial 30, and as pictured in Fig. 7, these two separated elements are driven toward one another until the vial is fully coupled to the transfer apparatus -- a condition illustrated in Fig. 3. The ' 1 r l'r, ,, ,r ~j L~ ~!
conical organization of fingers 26b tends to guide and direct the vial centrally into vial-coupling end 24b_, and into a condition with spike 24d centrally piercing the stopper in the vial. The inner ends of fingers 26b bear against the underside shoulder of the band in the vial, and tend to hold the vial in place against involuntary ejection under the now-present influence of the deflected central portion of the vial's stopper.
Focusing attention on Fig. 9 which, as has been mentioned, is an enlarged detail derived from Fig. 8, one can see the central deflection which exists in the stopper, and that ports 24i are received well within the stopper's cup in the stopper in the vial, and closely adjacent the base of the cup.
Preferably, now, by up-ending tl'~is filly connected organization so that vial 30 is inverted, the plunger in the syringe is withdrawn, as indicated by the arrow in Fig. 8, to draw liquid diluent from the vial into the body of the syringe. The fact that ports 24i are well within the cup in the stopper, and closely adjacent the base of the cup, results in substantial assurance that essentially all of the liquid in the vial will be gathered.
Ne,~ct, the now-emptied small vial is withdrawn by pulling it to the left away from the coupled syringe, as indicated in Fig. 10, with such withdrawal action automatically causing adaptor 26 to separate from device 24 and to remain attached to the smaller vial. Such convenient, automatic separation of adaptor 26 and device 24 is an advantageous feature of the apparatus of the invention.
Next, and looking now at Fig. 11, the mouth end of a larger-size vial, such as vial 32, is directed as indicated toward vial-coupling end 24b, with the portion of shroud/collar 24e which extends longitudinally beyond spike 26d tending to gather, guide and centralize the mouth end of the vial relative to spike 24d. This action results in full coupling of the larder vial with device 24, as indicated in Fig. 12. Under these circumstances, and now referring to Fig. 13, along with Fig. 12, one ~~ ~~"°~
can see that the underside shoulder of the band in vial 32 is borne against and therefore gripped by protuberances 24~ and that ports 24i are positioned within the cup in the vial's stopper closely adjacent the base of that cup. Protuberances 24f tend to hold this larger vial in place against the same land of involuntary ejection mentioned earlier -- such ejection being promoted under the influence of central deflection in the stopper, which deflection is clearly evident in Fig. 13.
The plunger in the syringe is then moved as indicated by the double-ended arrow in Fig. 12, first inwardly into the body of the syringe to eject diluent liquid into vial 32 for the purpose of mixing and blending with the dry powdered medicine initially resident in vial 32, and after mixing, then outwardly from the body of the syringe to extract fully-blended pharmaceutical liquid.
With the construction of the apparatus of the invention as described, and considering the construction of the liquid-passage structure, liquid ejected into vial 32 exits ports 24i substantially radially against the adjacent surfaces of the stopper cup, and this action tends to cause liquid entering the vial to flow outwardly and downwardly along the inside wall of the vessel in the vial so as to minimize unwanted foaming. Ordinarily, this ejection activity takes place with the vial generally upright, or at least at some upwardly inclined angle. Withdrawing of blended material from vial 32 is typically accomplished by inverting the coupled assemblage so that substantially all of the blended material in the vial ultimately gathers near the base of the stopper's cup where it is readily accessible for extraction through into ports 24i.
With the syringe now filled with a fully-prepared dispensible liquid pharmaceutical, the syringe is decoupled from device 24 as indicated by Fig. 14.
In modern practice, the constituent elements of the apparatus of the invention are not re-used, and so remain with the now-spent vials with which they are discharged.
_ ~ i;, Reviewing very briefly an aspect of the procedure which has just been described, one should note that, because of the positional relationship which exists in each case where a vial is fully coupled for liquid transfer, the acting vial-grip structure is positioned relative to ports 24i in such a manner that the ports become properly positioned witrin the associated stopper cup.
Under circumstances where the apparatus of the invention is intended to be used in a single-size, two-vial procedure, only a device like liquid-transfer device 24 needs to be employed. The manner of practicing this procedure should be clear from the description which has just been given above, recognizing that decoupling of the first-used val in the procedure is done without removing device 24 from the communication end of a coupled syringe.
Accordingly, the apparatus of the invention clearly meets the objectives and offer s the advantages ascribed to it earlier herein. For example, it affords ready accommodation both of same-vial-sizes and of different-vial-sizes in a very easy manner. Foaming problems are greatly minimized, if not all together avoided. Gathering and withdrawing of liquid from a vial is facilitated by the close positioning which exists between the ports in the apparatus of the invention and the base of a cup in the stopper of a coupled vial.
While a preferred structural form of the invention has been described and illustrated herein, we appreciate that certain variations and modifications may be made without departing from the spirit of the invention.
Claims (23)
1. An elongate, unitary liquid-transfer device operatively interposable between a syringe and a vial, and which is constructed for use with a vial of the type including a vessel with a mouth closed by a pierceable stopper, and where the stopper includes a hollow-interior, central, annular, projecting wall structure with an open end defining a cup with a base facing the interior of the vessel, said device comprising a syringe-coupling end, a vial-coupling end, and liquid-passage structure including an elongate channel extending axially centrally in said device from said syringe-coupling end toward said vial-coupling end, and at least one laterally facing port communicating with said channel adjacent said vial-coupling end, said liquid-passage structure, at the region of communication between said channel and said port, being constructed to limit liquid flow out of said port predominantly to generally radial flow relative to the length of said channel, said vial-coupling end being constructed whereby, with the device coupled to such a vial, said port is located within the stopper's cup and closely adjacent the cup's base.
2. The device of claim 1 which further includes vial-grip structure located adjacent said vial-coupling end.
3. The device of claim 2, wherein said vial-grip structure is located downstream from said port relative to said channel.
4. The device of claim 1, 2 or 3, wherein said region of communication between said channel and said port is at least partially defined by a generally planar barrier wall which extends in a plane substantially normal to the length of said channel.
5. The device of any one of claims 1 to 4, wherein said vial-coupling end is formed with a central vial-stopper-piercing spike which includes both said port and a portion of said channel, and an annular shroud/collar symmetrically circumsurrounding said spike.
6. The device of claim 5, wherein said shroud/collar projects longitudinally beyond said spike.
7. The device of claim 2, wherein said vial-coupling end is formed with a central vial-stopper-piercing spike which includes both said port and a portion of said channel, and an annular shroud/collar symmetrically circumsurrounding said spike, and said vial-grip structure includes at least one protuberance formed on the inside wall of said shroud/collar, with said protuberance located downstream relative to said port.
8. The device of any one of claims 1 to 7, wherein said port has an exit profile which has maximum transverse dimensions that lie in the range of about 0.02- to about 0.03-inches.
9. The device of claim 8, wherein said exit profile has a cross-sectional area in the range of about 0.0004-in2 to about 0.0009-in2.
10. Liquid-transfer apparatus operatively interposable between a syringe and a vial, and accommodating sequential operative coupling first to the top of a vial having one size, and thereafter to the top of a vial having another, larger size, said apparatus comprising a liquid-transfer device including a syringe-coupling end, a vial-coupling end and liquid-passage structure effectively communicating between said ends, said vial-coupling end being sized for direct coupling to the top of a vial having such other, larger size, and a vial-coupling adaptor removably receivable in a connected relationship with said vial-coupling end to adapt the same for coupling of the apparatus to the top of a vial having such smaller, one size.
11. The apparatus of claim 10, wherein the connected relationship mentioned is a nested relationship.
12. The apparatus of claim 10 or claim 11, wherein said liquid-passage structure includes an elongate channel extending axially centrally in said device from said syringe-coupling end toward said vial-coupling end, and at least one laterally facing port communicating with said channel adjacent said vial-coupling end, said liquid-passage structure, at the region of communication between said channel and said port, being constructed to limit liquid flow out of said port predominantly to generally radial flow relative to the length of said channel.
13. The apparatus of claim 12, wherein said port has an exit profile which has maximum transverse dimensions that lie in the range of about 0.02- to about 0.03-inches.
14. The apparatus of claim 13, wherein said exit profile has a cross-sectional area in the range of about 0.0004-in2 to about 0.0009-in2.
15. The apparatus of any one of claims 12 to 14, wherein said liquid-transfer device further includes vial-grip structure located adjacent said vial-coupling end.
16. The apparatus of claim 15, wherein said vial-grip structure is disposed downstream from said port relative to said channel.
17. The apparatus of claim 12, wherein said adaptor includes vial-grip structure.
18. The apparatus of claim 17 in which, with the adaptor in a connected relationship with said vial-coupling end, said vial-grip structure is positioned downstream from said port relative to said channel.
19. The apparatus of claims 15, 16, 17 or 18 which is constructed for use with such different-sized vials each of a type including a vessel, with a mouth closed by a pierceable stopper, and where each such stopper includes a hollow-interior, central, annular, projecting wall structure with an open end defining a cup with a base facing the interior of the vessel, and wherein the positional relationship which exists between said port and said vial-grip structure, under circumstances with the device coupled to such a vial, is such that said port is located within the stopper's cup and closely adjacent the cup's base.
17a
17a
20. The apparatus of claim 10, wherein said vial-coupling end includes an annular shroud/collar sized to receive the top of a vial having such other, larger size, and said adaptor takes the form generally of an annular slider, slidably fittable within said shroud/collar.
21. The apparatus of claim 20, wherein said slider includes a vial-facing end, and conically distributed spring fingers converging inwardly from said end, which fingers act as a vial-grip structure.
22. A method of transferring liquid between a syringe and a vial, where the vial is of the type including a pierceable stopper having an inwardly facing cup with an inwardly facing base, said method comprising utilizing a transfer device which includes a syringe-coupling end, a vial-coupling end, and liquid-passage structure communicating therebetween and including at least one laterally-facing port open adjacent the vial-coupling end, coupling a selected syringe and a selected vial 17b to such respective ends, and by said coupling action, as such relates to the selected vial, piercing the vial's stopper and establishing a coupled condition with the vial wherein the mentioned port in the liquid-passage structure is positioned within the vial's stopper's cup, closely adjacent the cup's base.
23. A method of transferring liquid between a syringe and a vial under circumstances that require accommodating sequential operative coupling first to the top of the vial having one size, and thereafter to the top of a vial having another larger size, said method comprising utilizing liquid-transfer apparatus which includes a liquid-transfer device including a syringe-coupling end, a vial-coupling end sized to receive directly the top of a vial having such other, larger size, and liquid-passage structure communicating between these ends, and a vial-coupling adaptor removably receivable in a connected relationship with the mentioned vial-coupling end to adapt the same for coupling of the apparatus to the top of a vial having such smaller, one size, establishing a connected relationship between the liquid-transfer device and the vial-coupling adaptor, coupling a selected syringe and a selected vial having such smaller, one size, performing a liquid-transfer operation between the selected syringe and the selected vial, decoupling the first selected vial, and by said decoupling automatically disconnecting the vial-coupling adaptor and the liquid-transfer device, selecting a second vial of the type characterized by such other, larger size and coupling the same to the vial-coupling end in the liquid-transfer device, and performing at least one other liquid-transfer operation.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/586,566 | 1996-01-12 | ||
| US08/586,566 US5893397A (en) | 1996-01-12 | 1996-01-12 | Medication vial/syringe liquid-transfer apparatus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2192623A1 CA2192623A1 (en) | 1997-07-13 |
| CA2192623C true CA2192623C (en) | 2000-06-27 |
Family
ID=24346263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2192623 Expired - Fee Related CA2192623C (en) | 1996-01-12 | 1996-12-11 | Medication vial/syringe liquid/transfer apparatus |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5893397A (en) |
| EP (1) | EP0783879B1 (en) |
| JP (1) | JP3916713B2 (en) |
| AT (1) | ATE240709T1 (en) |
| CA (1) | CA2192623C (en) |
| DE (1) | DE69628275T2 (en) |
| DK (1) | DK0783879T3 (en) |
| ES (1) | ES2200041T3 (en) |
| PT (1) | PT783879E (en) |
Families Citing this family (451)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL114960A0 (en) | 1995-03-20 | 1995-12-08 | Medimop Medical Projects Ltd | Flow control device |
| US6475183B1 (en) * | 1998-06-03 | 2002-11-05 | Baxter International Inc. | Direct dual filling device for sealing agents |
| US6093183A (en) * | 1998-08-07 | 2000-07-25 | Pavkovich; Mary | Safety Intravenous connector |
| US6406455B1 (en) * | 1998-12-18 | 2002-06-18 | Biovalve Technologies, Inc. | Injection devices |
| US6689095B1 (en) * | 1999-04-22 | 2004-02-10 | Gilbert Garitano | Needleless permanent makeup and tattoo device |
| US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
| US6569123B2 (en) | 1999-10-14 | 2003-05-27 | Becton, Dickinson And Company | Prefillable intradermal injector |
| US20020193740A1 (en) | 1999-10-14 | 2002-12-19 | Alchas Paul G. | Method of intradermally injecting substances |
| US6569143B2 (en) | 1999-10-14 | 2003-05-27 | Becton, Dickinson And Company | Method of intradermally injecting substances |
| US6843781B2 (en) * | 1999-10-14 | 2005-01-18 | Becton, Dickinson And Company | Intradermal needle |
| US6776776B2 (en) * | 1999-10-14 | 2004-08-17 | Becton, Dickinson And Company | Prefillable intradermal delivery device |
| US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
| US6321941B1 (en) * | 2000-04-20 | 2001-11-27 | The Procter & Gamble Company | Consumer safe fitment for connecting a reservoir to a dispensing appliance |
| WO2001051109A1 (en) * | 2000-01-07 | 2001-07-19 | Biovalve Technologies, Inc. | Injection device |
| US8565860B2 (en) | 2000-08-21 | 2013-10-22 | Biosensors International Group, Ltd. | Radioactive emission detector equipped with a position tracking system |
| US8909325B2 (en) | 2000-08-21 | 2014-12-09 | Biosensors International Group, Ltd. | Radioactive emission detector equipped with a position tracking system and utilization thereof with medical systems and in medical procedures |
| US8489176B1 (en) | 2000-08-21 | 2013-07-16 | Spectrum Dynamics Llc | Radioactive emission detector equipped with a position tracking system and utilization thereof with medical systems and in medical procedures |
| GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
| WO2002051470A2 (en) * | 2000-11-30 | 2002-07-04 | Biovalve Technologies, Inc. | Injection systems |
| GB0100756D0 (en) | 2001-01-11 | 2001-02-21 | Powderject Res Ltd | Needleless syringe |
| WO2002074336A2 (en) | 2001-02-23 | 2002-09-26 | Glaxosmithkline Biologicals S.A. | Influenza vaccine formulations for intradermal delivery |
| JP2004529754A (en) | 2001-03-14 | 2004-09-30 | ペンジェット・コーポレーション | System and method for removing dissolved gases from a solution |
| AU2002248537B2 (en) * | 2001-03-27 | 2006-07-13 | Eli Lilly And Company | Kit including side firing syringe needle for preparing a drug in an injection pen cartridge |
| GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
| US6613010B2 (en) | 2001-04-13 | 2003-09-02 | Penjet Corporation | Modular gas-pressured needle-less injector |
| US20050192530A1 (en) * | 2001-04-13 | 2005-09-01 | Penjet Corporation | Method and apparatus for needle-less injection with a degassed fluid |
| US6755220B2 (en) | 2001-04-27 | 2004-06-29 | Penjet Corporation | Method and apparatus for filling or refilling a needle-less injector |
| US20100221284A1 (en) | 2001-05-30 | 2010-09-02 | Saech-Sisches Serumwerk Dresden | Novel vaccine composition |
| MY134424A (en) | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
| WO2003002069A2 (en) * | 2001-06-29 | 2003-01-09 | Becton, Dickinson And Company | Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
| US20060018877A1 (en) * | 2001-06-29 | 2006-01-26 | Mikszta John A | Intradermal delivery of vacccines and therapeutic agents |
| JP4817564B2 (en) * | 2001-09-28 | 2011-11-16 | 株式会社細川洋行 | Needle case and infusion container |
| US6824526B2 (en) | 2001-10-22 | 2004-11-30 | Penjet Corporation | Engine and diffuser for use with a needle-less injector |
| US6989891B2 (en) | 2001-11-08 | 2006-01-24 | Optiscan Biomedical Corporation | Device and method for in vitro determination of analyte concentrations within body fluids |
| US6875205B2 (en) * | 2002-02-08 | 2005-04-05 | Alaris Medical Systems, Inc. | Vial adapter having a needle-free valve for use with vial closures of different sizes |
| US7238167B2 (en) * | 2002-06-04 | 2007-07-03 | Bioject Inc. | Needle-free injection system |
| US7156823B2 (en) * | 2002-06-04 | 2007-01-02 | Bioject Inc. | High workload needle-free injection system |
| JP4427965B2 (en) * | 2002-07-02 | 2010-03-10 | ニプロ株式会社 | Chemical container with communication means |
| US6935384B2 (en) * | 2003-02-19 | 2005-08-30 | Bioject Inc. | Needle-free injection system |
| US7261698B2 (en) * | 2003-04-24 | 2007-08-28 | Sherwood Services Ag | Transfer needle safety apparatus |
| CN1833030B (en) | 2003-05-22 | 2014-07-23 | 美国弗劳恩霍夫股份有限公司 | Recombinant carrier molecule for expression, delivery and purification of target polypeptides |
| FR2858931B1 (en) * | 2003-08-21 | 2007-04-13 | Becton Dickinson France | DEVICE FOR ORAL ADMINISTRATION OF A MEDICINAL PRODUCT |
| AU2003270473A1 (en) * | 2003-09-09 | 2005-04-27 | University Of Florida | Desferrithiocin derivatives and their use as iron chelators |
| US6997916B2 (en) * | 2004-01-02 | 2006-02-14 | Smiths Medical Asd, Inc. | Fluid transfer holder assembly and a method of fluid transfer |
| US8571881B2 (en) | 2004-11-09 | 2013-10-29 | Spectrum Dynamics, Llc | Radiopharmaceutical dispensing, administration, and imaging |
| US8586932B2 (en) | 2004-11-09 | 2013-11-19 | Spectrum Dynamics Llc | System and method for radioactive emission measurement |
| US7968851B2 (en) | 2004-01-13 | 2011-06-28 | Spectrum Dynamics Llc | Dynamic spect camera |
| US9470801B2 (en) | 2004-01-13 | 2016-10-18 | Spectrum Dynamics Llc | Gating with anatomically varying durations |
| WO2005067383A2 (en) | 2004-01-13 | 2005-07-28 | Spectrum Dynamics Llc | Multi-dimensional image reconstruction |
| WO2008010227A2 (en) | 2006-07-19 | 2008-01-24 | Spectrum Dynamics Llc | Imaging protocols |
| IL161660A0 (en) | 2004-04-29 | 2004-09-27 | Medimop Medical Projects Ltd | Liquid drug delivery device |
| EP1778957A4 (en) | 2004-06-01 | 2015-12-23 | Biosensors Int Group Ltd | Radioactive-emission-measurement optimization to specific body structures |
| EP2181714A3 (en) | 2004-09-22 | 2010-06-23 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition for use in vaccination against staphylococcei |
| US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
| US9316743B2 (en) | 2004-11-09 | 2016-04-19 | Biosensors International Group, Ltd. | System and method for radioactive emission measurement |
| US8615405B2 (en) * | 2004-11-09 | 2013-12-24 | Biosensors International Group, Ltd. | Imaging system customization using data from radiopharmaceutical-associated data carrier |
| US9943274B2 (en) | 2004-11-09 | 2018-04-17 | Spectrum Dynamics Medical Limited | Radioimaging using low dose isotope |
| US8423125B2 (en) | 2004-11-09 | 2013-04-16 | Spectrum Dynamics Llc | Radioimaging |
| EP1827505A4 (en) | 2004-11-09 | 2017-07-12 | Biosensors International Group, Ltd. | Radioimaging |
| ES2354018T3 (en) * | 2005-02-14 | 2011-03-09 | Medimop Medical Projects Ltd. | MEDICAL DEVICE FOR THE IN SITU RECONSTITUTION OF LIQUID DRUGS IN MEDICINAL CONTAINERS. |
| US20070060904A1 (en) * | 2005-03-14 | 2007-03-15 | Becton, Dickinson And Company | Filling system and method for syringes with short needles |
| US20090081253A1 (en) | 2005-03-23 | 2009-03-26 | Glaxosmithkline Biologicals S.A. | Composition |
| MX2007012226A (en) | 2005-04-04 | 2007-12-10 | Univ Florida | Desferrithiocin polyether analogues. |
| US8644910B2 (en) | 2005-07-19 | 2014-02-04 | Biosensors International Group, Ltd. | Imaging protocols |
| US8837793B2 (en) | 2005-07-19 | 2014-09-16 | Biosensors International Group, Ltd. | Reconstruction stabilizer and active vision |
| KR101446025B1 (en) | 2005-08-03 | 2014-10-01 | 아이바이오, 인크. | Compositions and methods for production of immunoglobulins |
| ATE529088T1 (en) | 2005-08-11 | 2011-11-15 | Medimop Medical Projects Ltd | TRANSFER DEVICES FOR LIQUID MEDICINAL PRODUCTS FOR FAIL-SAFE CORRECT LATCH CONNECTION ON MEDICAL AMPOULES |
| DK1957028T3 (en) * | 2005-10-30 | 2017-09-11 | Medimop Medical Projects Ltd | Needleless additive control valve |
| TWI457133B (en) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | Novel composition |
| WO2007070682A2 (en) * | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | System for screening particles |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| TW201350129A (en) | 2005-12-22 | 2013-12-16 | Glaxosmithkline Biolog Sa | Streptococcus pneumoniae immunogenic composition comprising capsular saccharide conjugates, vaccine and kit comprising the same and uses thereof |
| KR20080106433A (en) * | 2006-02-13 | 2008-12-05 | 프라운호퍼 유에스에이, 인코포레이티드 | Influenza antigens, vaccine compositions, and related methods |
| US8277816B2 (en) * | 2006-02-13 | 2012-10-02 | Fraunhofer Usa, Inc. | Bacillus anthracis antigens, vaccine compositions, and related methods |
| AU2007215082B2 (en) * | 2006-02-13 | 2012-07-12 | Ibio, Inc. | HPV antigens, vaccine compositions, and related methods |
| US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
| EP1998684A4 (en) * | 2006-03-10 | 2014-09-17 | Massachusetts Inst Technology | Triggered self-assembly conjugates and nanosystems |
| US7666912B2 (en) | 2006-03-23 | 2010-02-23 | Massachusetts Eye And Ear Infirmary | Compositions and methods for reducing body fat |
| CA2647441C (en) | 2006-03-30 | 2021-02-23 | Glaxosmithkline Biologicals S.A. | Immunogenic composition comprising staphylococcus aureus saccharides |
| ES2776100T3 (en) | 2006-03-31 | 2020-07-29 | Massachusetts Inst Technology | System for targeted delivery of therapeutic agents |
| US20090325944A1 (en) * | 2006-04-12 | 2009-12-31 | Suzanne Walker Kahne | Methods and Compositions for Modulating Glycosylation |
| US8894974B2 (en) | 2006-05-11 | 2014-11-25 | Spectrum Dynamics Llc | Radiopharmaceuticals for diagnosis and therapy |
| JP5630998B2 (en) | 2006-05-15 | 2014-11-26 | マサチューセッツ インスティテュート オブ テクノロジー | Polymers for functional particles |
| EP2526919B1 (en) | 2006-05-25 | 2016-10-05 | Bayer Healthcare LLC | Reconstitution device |
| ES2570334T3 (en) | 2006-06-02 | 2016-05-17 | Harvard College | Surface protein remodeling |
| WO2007150030A2 (en) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
| US7601966B2 (en) * | 2006-06-28 | 2009-10-13 | Spectrum Dynamics Llc | Imaging techniques for reducing blind spots |
| DK2422810T3 (en) | 2006-07-17 | 2014-11-24 | Glaxosmithkline Biolog Sa | Influenza vaccine |
| WO2008021367A2 (en) | 2006-08-11 | 2008-02-21 | President And Fellows Of Harvard College | Moenomycin biosynthesis-related compositions and methods of use thereof |
| US20090269342A1 (en) * | 2006-08-14 | 2009-10-29 | Massachusetts Institute Of Technology | Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto |
| AU2007284496A1 (en) * | 2006-08-14 | 2008-02-21 | Massachusetts Institute Of Technology | Glycan data mining system |
| US7942845B2 (en) * | 2006-09-19 | 2011-05-17 | Bioject, Inc. | Needle-free injector and process for providing serial injections |
| US7547293B2 (en) | 2006-10-06 | 2009-06-16 | Bioject, Inc. | Triggering mechanism for needle-free injector |
| JO3598B1 (en) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | Boronic acids and esters as inhibitors of fatty acid amide hydrolase |
| EP2433648A3 (en) | 2006-10-12 | 2012-04-04 | GlaxoSmithKline Biologicals S.A. | Vaccine comprising an oil in water emulsion adjuvant |
| ES2397714T3 (en) | 2006-10-12 | 2013-03-08 | Glaxosmithkline Biologicals S.A. | Vaccine comprising an oil-in-water emulsion adjuvant |
| US8610075B2 (en) | 2006-11-13 | 2013-12-17 | Biosensors International Group Ltd. | Radioimaging applications of and novel formulations of teboroxime |
| WO2008147456A2 (en) * | 2006-11-20 | 2008-12-04 | Massachusetts Institute Of Technology | Drug delivery systems using fc fragments |
| MX2009005727A (en) | 2006-12-01 | 2009-08-27 | Anterios Inc | Amphiphilic entity nanoparticles. |
| WO2008073856A2 (en) * | 2006-12-08 | 2008-06-19 | Massachusetts Institute Of Technology | Delivery of nanoparticles and/or agents to cells |
| WO2008075362A2 (en) | 2006-12-20 | 2008-06-26 | Spectrum Dynamics Llc | A method, a system, and an apparatus for using and processing multidimensional data |
| DK2474525T3 (en) | 2006-12-26 | 2020-07-13 | Lantheus Medical Imaging Inc | Ligands for imaging cardiac innervation |
| EP2118123B1 (en) | 2007-01-31 | 2015-10-14 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| EP2134830A2 (en) * | 2007-02-09 | 2009-12-23 | Massachusetts Institute of Technology | Oscillating cell culture bioreactor |
| US7744563B2 (en) * | 2007-02-23 | 2010-06-29 | Bioject, Inc. | Needle-free injection devices and drug delivery systems therefor |
| US8324397B2 (en) | 2007-03-15 | 2012-12-04 | University Of Florida Research Foundation, Inc. | Desferrithiocin polyether analogues |
| US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
| JP5631201B2 (en) | 2007-03-28 | 2014-11-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Stitched polypeptide |
| JP2010523595A (en) | 2007-04-04 | 2010-07-15 | マサチューセッツ インスティテュート オブ テクノロジー | Poly (amino acid) targeting part |
| WO2008124634A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
| IL182605A0 (en) | 2007-04-17 | 2007-07-24 | Medimop Medical Projects Ltd | Fluid control device with manually depressed actuator |
| US8778348B2 (en) * | 2007-04-28 | 2014-07-15 | Ibio Inc. | Trypanosoma antigens, vaccine compositions, and related methods |
| GB0708758D0 (en) * | 2007-05-04 | 2007-06-13 | Powderject Res Ltd | Particle cassettes and process thereof |
| WO2008144575A2 (en) | 2007-05-18 | 2008-11-27 | Optiscan Biomedical Corporation | Fluid injection and safety system |
| PT2175881E (en) * | 2007-06-14 | 2012-10-22 | Crucell Switzerland Ag | Intradermal influenza vaccine |
| US8524444B2 (en) | 2007-06-15 | 2013-09-03 | President And Fellows Of Harvard College | Methods and compositions for detections and modulating O-glycosylation |
| AU2008267208B2 (en) | 2007-06-26 | 2012-01-19 | Glaxosmithkline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
| CA2692933C (en) | 2007-07-11 | 2016-10-18 | Fraunhofer Usa, Inc. | Yersinia pestis antigens, vaccine compositions, and related methods |
| JP2010538744A (en) | 2007-09-18 | 2010-12-16 | メディモップ・メディカル・プロジェクツ・リミテッド | Drug mixing injection device |
| IL186290A0 (en) | 2007-09-25 | 2008-01-20 | Medimop Medical Projects Ltd | Liquid drug delivery devices for use with syringe having widened distal tip |
| DE102007046951B3 (en) * | 2007-10-01 | 2009-02-26 | B. Braun Melsungen Ag | Device for introducing a medicament into an infusion container |
| EP2205074A4 (en) * | 2007-10-04 | 2013-07-31 | Harvard College | Moenomycin analogs, methods of synthesis, and uses thereof |
| WO2009051837A2 (en) | 2007-10-12 | 2009-04-23 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
| US8521253B2 (en) | 2007-10-29 | 2013-08-27 | Spectrum Dynamics Llc | Prostate imaging |
| US20090137949A1 (en) * | 2007-11-26 | 2009-05-28 | Bioject Inc. | Needle-free injection device with nozzle auto-disable |
| US8617099B2 (en) * | 2007-11-26 | 2013-12-31 | Bioject Inc. | Injection device plunger auto-disable |
| CA2646261A1 (en) * | 2007-12-14 | 2009-06-14 | Tyco Healthcare Group Lp | Blood collection device with tube retaining structure |
| WO2009089119A2 (en) * | 2008-01-03 | 2009-07-16 | Massachusetts Institute Of Technology | Decoy influenza therapies |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| PE20091838A1 (en) * | 2008-04-09 | 2009-12-18 | Infinity Pharmaceuticals Inc | FATTY ACID AMIDA HYDROLASE INHIBITORS |
| CN102099052A (en) | 2008-04-16 | 2011-06-15 | 葛兰素史密丝克莱恩生物有限公司 | Vaccine |
| CN102066405B (en) * | 2008-04-28 | 2015-09-30 | 哈佛大学校长及研究员协会 | For the supercharged proteins of cell-penetrating |
| US20110212157A1 (en) | 2008-06-26 | 2011-09-01 | Anterios, Inc. | Dermal delivery |
| DK2318832T3 (en) | 2008-07-15 | 2014-01-20 | Academia Sinica | Glycan arrays on PTFE-like aluminum coated slides and related methods |
| EP2356139A4 (en) | 2008-07-23 | 2013-01-09 | Harvard College | Ligation of stapled polypeptides |
| WO2010011318A2 (en) * | 2008-07-23 | 2010-01-28 | Massachusetts Institute Of Technology | Activatiqn of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survival |
| WO2010037046A1 (en) | 2008-09-28 | 2010-04-01 | Fraunhofer Usa, Inc. | Humanized neuraminidase antibody and methods of use thereof |
| US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
| US8343498B2 (en) * | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| US8343497B2 (en) * | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| US9974844B2 (en) | 2008-11-17 | 2018-05-22 | The Regents Of The University Of Michigan | Cancer vaccine compositions and methods of using the same |
| EP2376619A4 (en) | 2008-12-15 | 2012-07-04 | Greenlight Biosciences Inc | Methods for control of flux in metabolic pathways |
| EP2379728A4 (en) * | 2008-12-22 | 2016-04-13 | Greenlight Biosciences Inc | Compositions and methods for the production of a compound |
| US20100160889A1 (en) * | 2008-12-22 | 2010-06-24 | Baxter International Inc. | Vial access spike assembly |
| US8864725B2 (en) | 2009-03-17 | 2014-10-21 | Baxter Corporation Englewood | Hazardous drug handling system, apparatus and method |
| USD641080S1 (en) | 2009-03-31 | 2011-07-05 | Medimop Medical Projects Ltd. | Medical device having syringe port with locking mechanism |
| EP2416660B1 (en) | 2009-04-07 | 2014-07-02 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| CA2757622A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| JP2012525146A (en) | 2009-04-28 | 2012-10-22 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | Overcharged protein for cell penetration |
| US9149465B2 (en) * | 2009-05-18 | 2015-10-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
| US8927551B2 (en) * | 2009-05-18 | 2015-01-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
| US8765735B2 (en) * | 2009-05-18 | 2014-07-01 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
| JP2012528858A (en) | 2009-06-01 | 2012-11-15 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | O-GlcNAc transferase inhibitor and use thereof |
| USD616984S1 (en) | 2009-07-02 | 2010-06-01 | Medimop Medical Projects Ltd. | Vial adapter having side windows |
| US9163330B2 (en) | 2009-07-13 | 2015-10-20 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| US8338788B2 (en) | 2009-07-29 | 2012-12-25 | Spectrum Dynamics Llc | Method and system of optimized volumetric imaging |
| GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| EP2483307A1 (en) | 2009-09-29 | 2012-08-08 | Fraunhofer USA, Inc. | Influenza hemagglutinin antibodies, compositions, and related methods |
| USD630732S1 (en) | 2009-09-29 | 2011-01-11 | Medimop Medical Projects Ltd. | Vial adapter with female connector |
| IL201323A0 (en) | 2009-10-01 | 2010-05-31 | Medimop Medical Projects Ltd | Fluid transfer device for assembling a vial with pre-attached female connector |
| CA2778105C (en) | 2009-10-23 | 2019-04-02 | Amgen Inc. | Vial adapter and system |
| IL202070A0 (en) | 2009-11-12 | 2010-06-16 | Medimop Medical Projects Ltd | Inline liquid drug medical device |
| IL202069A0 (en) | 2009-11-12 | 2010-06-16 | Medimop Medical Projects Ltd | Fluid transfer device with sealing arrangement |
| US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| AU2010343102B2 (en) | 2009-12-29 | 2016-03-24 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| CA2787940C (en) | 2010-01-27 | 2020-01-07 | Massachusetts Institute Of Technology | Engineered polypeptide agents for targeted broad spectrum influenza neutralization |
| RU2569061C2 (en) | 2010-02-03 | 2015-11-20 | Инфинити Фармасьютикалз, Инк. | Inhibitors of amide-hydrolase of fatty acids |
| JP5709905B2 (en) | 2010-02-24 | 2015-04-30 | メディモップ・メディカル・プロジェクツ・リミテッド | Liquid transfer device including vial adapter with vent |
| CN102711712B (en) | 2010-02-24 | 2014-08-13 | 麦迪麦珀医疗工程有限公司 | Fluid transfer assembly with venting arrangement |
| JP5827962B2 (en) | 2010-03-08 | 2015-12-02 | スローン ケタリング インスティテュート フォア キャンサー リサーチ | Cdc7 kinase inhibitors and uses thereof |
| GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
| GB201003920D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
| US9102697B2 (en) | 2010-03-22 | 2015-08-11 | President And Fellows Of Harvard College | Trioxacarcins and uses thereof |
| WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
| CA2798330A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
| WO2011140296A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals | Triazoles as inhibitors of fatty acid synthase |
| CA2797786C (en) | 2010-05-07 | 2020-09-22 | Greenlight Biosciences, Inc. | Methods for control of flux in metabolic pathways through enzyme relocation |
| KR101726471B1 (en) | 2010-05-11 | 2017-04-12 | 랜티우스 메디컬 이메징, 인크. | Compositions, methods and systems for the synthesis and use of imaging agents |
| US9193989B2 (en) | 2010-06-18 | 2015-11-24 | Taiho Pharmaceutical Co., Ltd. | PRPK-TPRKB modulators and uses thereof |
| JPWO2012002314A1 (en) * | 2010-06-30 | 2013-08-22 | テルモ株式会社 | Connectors and connector assemblies |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK2603600T3 (en) | 2010-08-13 | 2019-03-04 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES |
| JP6280367B2 (en) | 2010-08-31 | 2018-02-14 | グリーンライト バイオサイエンシーズ インコーポレーテッドＧｒｅｅｎｌｉｇｈｔ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． | A method for the control of fluxes in metabolic pathways via protease manipulation |
| EP2640405A4 (en) | 2010-09-21 | 2015-04-15 | Massachusetts Inst Technology | Human-adapted ha polypeptides, vaccines, and influenza treatment |
| WO2012040459A2 (en) | 2010-09-22 | 2012-03-29 | President And Fellows Of Harvard College | Beta-catenin targeting peptides and uses thereof |
| PL3590949T3 (en) | 2010-10-01 | 2022-08-29 | Modernatx, Inc. | Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof |
| SG189236A1 (en) | 2010-10-04 | 2013-05-31 | Massachusetts Inst Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
| USD669980S1 (en) | 2010-10-15 | 2012-10-30 | Medimop Medical Projects Ltd. | Vented vial adapter |
| JP2013545749A (en) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | Heterocyclic compounds and uses thereof |
| IL209290A0 (en) | 2010-11-14 | 2011-01-31 | Medimop Medical Projects Ltd | Inline liquid drug medical device having rotary flow control member |
| MX347708B (en) | 2011-01-10 | 2017-05-09 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones. |
| ES2687494T3 (en) | 2011-01-19 | 2018-10-25 | Topokine Therapeutics, Inc. | Methods and compositions to reduce body fat |
| CN109464393A (en) | 2011-01-24 | 2019-03-15 | 安特里奥公司 | Nanoparticulate compositions |
| JP2014503586A (en) | 2011-01-24 | 2014-02-13 | アンテリオス， インコーポレイテッド | Oil composition |
| BR112013018920A2 (en) | 2011-01-24 | 2017-11-28 | Anterios Inc | nanoparticle compositions, formulations thereof and their uses |
| EP3510998A1 (en) | 2011-03-03 | 2019-07-17 | Tersus Pharmaceuticals, LLC | Compositions and methods comprising c16:1n7-palmitoleate |
| GB201103836D0 (en) | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
| WO2012135615A2 (en) | 2011-03-30 | 2012-10-04 | Brown University | Enopeptins, uses thereof, and methods of synthesis thereto |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| AU2012236573B2 (en) | 2011-03-31 | 2016-06-02 | Amgen Inc. | Vial adapter and system |
| IL212420A0 (en) | 2011-04-17 | 2011-06-30 | Medimop Medical Projects Ltd | Liquid drug transfer assembly |
| CA2834834A1 (en) | 2011-05-17 | 2012-11-22 | Glaxosmithkline Biologicals S.A. | Vaccine against streptococcus pneumoniae |
| WO2012177997A1 (en) | 2011-06-22 | 2012-12-27 | The General Hospital Corporation | Treatment of proteinopathies |
| WO2013009897A1 (en) | 2011-07-11 | 2013-01-17 | Medpro Safety Products, Inc. | Fluid delivery device and methods |
| US9220660B2 (en) | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
| PT3050588T (en) * | 2011-07-15 | 2018-05-29 | Antares Pharma Inc | Liquid-transfer adapter beveled spike |
| CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| JP6027610B2 (en) | 2011-07-19 | 2016-11-16 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | Heterocyclic compounds and uses thereof |
| DK2734510T3 (en) | 2011-07-22 | 2019-03-04 | Massachusetts Inst Technology | CLASS I-HISTONDEACETYLASES (HDAC) ACTIVATORS AND APPLICATIONS THEREOF |
| EP2751093A1 (en) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9550000B2 (en) | 2011-09-09 | 2017-01-24 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| JP2014526250A (en) | 2011-09-09 | 2014-10-06 | グリーンライト バイオサイエンシーズ インコーポレーテッド | Cell-free preparation of carbapenem |
| EP2755693A4 (en) | 2011-09-12 | 2015-05-20 | Moderna Therapeutics Inc | Engineered nucleic acids and methods of use thereof |
| US9630979B2 (en) | 2011-09-29 | 2017-04-25 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
| RS62993B1 (en) | 2011-10-03 | 2022-03-31 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| IL215699A0 (en) | 2011-10-11 | 2011-12-29 | Medimop Medical Projects Ltd | Liquid drug reconstitution assemblage for use with iv bag and drug vial |
| MX358886B (en) | 2011-10-18 | 2018-08-31 | Aileron Therapeutics Inc | Peptidomimetic macrocyles. |
| US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
| GB201119999D0 (en) | 2011-11-20 | 2012-01-04 | Glaxosmithkline Biolog Sa | Vaccine |
| GB201120000D0 (en) | 2011-11-20 | 2012-01-04 | Glaxosmithkline Biolog Sa | Vaccine |
| EP4144378A1 (en) | 2011-12-16 | 2023-03-08 | ModernaTX, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| BR112014014544A2 (en) | 2011-12-16 | 2017-06-13 | Univ Florida | Uses of 4'-Desferritiocine Analogs |
| US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
| USD737436S1 (en) | 2012-02-13 | 2015-08-25 | Medimop Medical Projects Ltd. | Liquid drug reconstitution assembly |
| USD674088S1 (en) | 2012-02-13 | 2013-01-08 | Medimop Medical Projects Ltd. | Vial adapter |
| USD720451S1 (en) | 2012-02-13 | 2014-12-30 | Medimop Medical Projects Ltd. | Liquid drug transfer assembly |
| AU2013221433B2 (en) | 2012-02-15 | 2018-01-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| CN112500466B (en) | 2012-02-15 | 2022-05-03 | 艾瑞朗医疗公司 | Peptidomimetic macrocycles |
| IL219065A0 (en) | 2012-04-05 | 2012-07-31 | Medimop Medical Projects Ltd | Fluid transfer device with manual operated cartridge release arrangement |
| EP2850090B1 (en) | 2012-04-06 | 2018-10-03 | President and Fellows of Harvard College | Chemoenzymatic methods for synthesizing moenomycin analogs |
| EP2834254A2 (en) | 2012-04-06 | 2015-02-11 | President and Fellows of Harvard College | Moenomycin analogs, methods of synthesis, and uses thereof |
| WO2013151697A1 (en) | 2012-04-06 | 2013-10-10 | President And Fellows Of Harvard College | Methods and compounds for identifying glycosyltransferase inhibitors |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
| US9597385B2 (en) | 2012-04-23 | 2017-03-21 | Allertein Therapeutics, Llc | Nanoparticles for treatment of allergy |
| WO2013169377A1 (en) | 2012-05-10 | 2013-11-14 | Massachusetts Institute Of Technology | Agents for influenza neutralization |
| US10799423B2 (en) | 2012-07-12 | 2020-10-13 | Ferring International Center S.A. | Liquid-transfer adapter beveled spike |
| JP2015521949A (en) | 2012-07-12 | 2015-08-03 | アンタレス・ファーマ・インコーポレーテッド | Chamfered spike on liquid transfer adapter |
| US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
| CA2879939A1 (en) | 2012-08-06 | 2014-02-13 | Glaxosmithkline Biologicals S.A. | Novel method |
| AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| CA2880701A1 (en) | 2012-08-18 | 2014-02-27 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
| IL221634A0 (en) | 2012-08-26 | 2012-12-31 | Medimop Medical Projects Ltd | Universal drug vial adapter |
| IL221635A0 (en) | 2012-08-26 | 2012-12-31 | Medimop Medical Projects Ltd | Drug vial mixing and transfer device for use with iv bag and drug vial |
| DK2872100T3 (en) | 2012-09-13 | 2017-07-10 | Medimop Medical Projects Ltd | Telescopic female adapter for drug ampoule |
| CA2925035C (en) | 2012-09-26 | 2021-05-25 | President And Fellows Of Harvard College | Proline-locked stapled peptides and uses thereof |
| US20150225471A1 (en) | 2012-10-01 | 2015-08-13 | President And Fellows Of Harvard College | Stabilized polypeptide insulin receptor modulators |
| LT2909204T (en) | 2012-10-12 | 2019-05-10 | The Broad Institute, Inc. | Gsk3 inhibitors and methods of use thereof |
| US10112927B2 (en) | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| RS58023B2 (en) | 2012-11-01 | 2021-12-31 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| BR112015009470A2 (en) | 2012-11-01 | 2019-12-17 | Aileron Therapeutics Inc | disubstituted amino acids and their methods of preparation and use |
| WO2014071247A1 (en) | 2012-11-02 | 2014-05-08 | Dana-Farber Cancer Institute, Inc. | Pyrrol-1 -yl benzoic acid derivates useful as myc inhibitors |
| MX2012013347A (en) | 2012-11-16 | 2013-10-08 | Leopoldo Meneses Fernandez | System for dispensing drugs. |
| EP2922542A4 (en) | 2012-11-21 | 2016-10-05 | Topokine Therapeutics Inc | Methods and compositions for locally increasing body fat |
| WO2014082065A1 (en) | 2012-11-26 | 2014-05-30 | President And Fellows Of Harvard College | Trioxacarcins, trioxacarcin-antibody conjugates, and uses thereof |
| SI2922554T1 (en) | 2012-11-26 | 2022-06-30 | Modernatx, Inc. | Terminally modified rna |
| EP2735300A1 (en) | 2012-11-26 | 2014-05-28 | Becton Dickinson France | Adaptor for multidose medical container |
| USD734868S1 (en) | 2012-11-27 | 2015-07-21 | Medimop Medical Projects Ltd. | Drug vial adapter with downwardly depending stopper |
| WO2014100695A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| CA2894130A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| UA118548C2 (en) | 2012-12-21 | 2019-02-11 | Епізайм, Інк. | Teatrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof |
| WO2014100716A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| USD713931S1 (en) | 2013-01-09 | 2014-09-23 | Central Garden & Pet Company | Sprayer |
| EP3434774A1 (en) | 2013-01-17 | 2019-01-30 | ModernaTX, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| CA2900008A1 (en) | 2013-02-07 | 2014-08-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
| WO2014124319A2 (en) | 2013-02-07 | 2014-08-14 | Massachusetts Institute Of Technology | Human adaptation of h5 influenza |
| US20140257204A1 (en) * | 2013-03-05 | 2014-09-11 | Stuart Robert Lessin | Apparatus for reconstituting and dispensing drugs for topical application |
| WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| BR112015022872A2 (en) | 2013-03-13 | 2017-11-07 | Harvard College | stapled and stitched polypeptides, their use, their method of preparation, their composition and amino acid |
| US20160024051A1 (en) | 2013-03-15 | 2016-01-28 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| CA2907915C (en) | 2013-04-03 | 2023-03-07 | Allertein Therapeutics, Llc | Immunomodulatory nanoparticle compositions comprising a plurality of nanoparticles comprising biodegradable or biocompatible polymers and hydrophilic and hydrophobic cellular components |
| WO2014165792A2 (en) | 2013-04-04 | 2014-10-09 | President And Fellows Of Harvard College | Macrolides and methods of their preparation and use |
| ES2774330T3 (en) | 2013-04-09 | 2020-07-20 | Massachusetts Inst Technology | Drug supply polymer and uses thereof |
| IL225734A0 (en) | 2013-04-14 | 2013-09-30 | Medimop Medical Projects Ltd | Ready-to-use drug vial assemblages including drug vial and drug vial closure having fluid transfer member, and drug vial closure therefor |
| US10301359B2 (en) | 2013-04-30 | 2019-05-28 | Massachusetts Institute Of Technology | Human adaptation of H3 influenza |
| US9315472B2 (en) | 2013-05-01 | 2016-04-19 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
| CN105246529B (en) | 2013-05-03 | 2019-06-14 | 科尼尔赛德生物医学公司 | Device and method for ocular injection |
| BR112015027555B1 (en) | 2013-05-10 | 2022-02-01 | Medimop Medical Projects Ltd | Medical device for use with a needleless syringe, a vial and a liquid carrier to fill the needleless syringe with an injection solution for injection into a patient |
| NO2753788T3 (en) | 2013-05-10 | 2018-06-16 | ||
| EP3003309B1 (en) | 2013-05-30 | 2020-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| WO2014197723A2 (en) | 2013-06-05 | 2014-12-11 | Massachusetts Institute Of Technology | Human adaptation of h7 ha |
| AU2014278231B2 (en) | 2013-06-11 | 2017-05-25 | KALA BIO, Inc. | Urea derivatives and uses thereof |
| US10227390B2 (en) | 2013-06-14 | 2019-03-12 | President And Fellows Of Harvard College | Stabilized polypeptide insulin receptor modulators |
| EP3013365B1 (en) | 2013-06-26 | 2019-06-05 | Academia Sinica | Rm2 antigens and use thereof |
| WO2014210564A1 (en) | 2013-06-27 | 2014-12-31 | Academia Sinica | Glycan conjugates and use thereof |
| RU2016105108A (en) | 2013-07-25 | 2017-08-30 | Дана-Фарбер Кэнсер Инститьют, Инк. | TRANSCRIPTION FACTOR INHIBITORS AND THEIR APPLICATION |
| CN105658807A (en) | 2013-08-05 | 2016-06-08 | 绿光生物科技股份有限公司 | Engineered proteins with protease cleavage site |
| AU2014304545A1 (en) | 2013-08-05 | 2016-02-25 | Glaxosmithkline Biologicals S.A. | Combination immunogenic compositions |
| USD765837S1 (en) | 2013-08-07 | 2016-09-06 | Medimop Medical Projects Ltd. | Liquid transfer device with integral vial adapter |
| USD767124S1 (en) | 2013-08-07 | 2016-09-20 | Medimop Medical Projects Ltd. | Liquid transfer device with integral vial adapter |
| WO2015019343A1 (en) | 2013-08-07 | 2015-02-12 | Medimop Medical Projects Ltd | Liquid transfer devices for use with infusion liquid containers |
| US9782476B2 (en) | 2013-09-06 | 2017-10-10 | Academia Sinica | Human iNKT cell activation using glycolipids with altered glycosyl groups |
| EP2851057A1 (en) * | 2013-09-23 | 2015-03-25 | Becton Dickinson France | Assembly for coupling an adaptor with a medical container |
| JP6284218B2 (en) * | 2013-09-26 | 2018-02-28 | テルモ株式会社 | Vial adapter |
| PE20160685A1 (en) | 2013-10-04 | 2016-07-23 | Infinity Pharmaceuticals Inc | HETEROCYCLIC COMPOUNDS AND USES OF THEM |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9982009B2 (en) | 2013-10-15 | 2018-05-29 | Massachusetts Institute Of Technology | Methods for treating polycystic kidney disease and polycystic liver disease |
| WO2015057958A2 (en) | 2013-10-16 | 2015-04-23 | Massachusetts Institute Of Technology | Enterobactin conjugates and uses thereof |
| US10047070B2 (en) | 2013-10-18 | 2018-08-14 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| AU2014337122B2 (en) | 2013-10-18 | 2019-01-03 | Dana-Farber Cancer Institute, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| WO2015061204A1 (en) | 2013-10-21 | 2015-04-30 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN106061261B (en) | 2013-11-01 | 2018-04-24 | 卡拉制药公司 | Crystal form of therapeutic compounds and application thereof |
| ES2743452T3 (en) * | 2013-11-06 | 2020-02-19 | Becton Dickinson & Co Ltd | System with adapter for closed fluid transfer |
| EP3065693B1 (en) | 2013-11-06 | 2019-02-06 | Becton Dickinson and Company Limited | Adapter for vial access device |
| JP6494631B2 (en) | 2013-12-24 | 2019-04-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Colchistatin analogues and their synthesis and use |
| WO2015109180A2 (en) | 2014-01-16 | 2015-07-23 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| US10793571B2 (en) | 2014-01-31 | 2020-10-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| AU2015226911B2 (en) | 2014-03-07 | 2018-03-01 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Non-narcotic CRMP2 peptides targeting sodium channels for chronic pain |
| MX2016012021A (en) | 2014-03-19 | 2017-04-13 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders. |
| CN106415244B (en) | 2014-03-27 | 2020-04-24 | 中央研究院 | Reactive marker compounds and uses thereof |
| JP6836400B2 (en) | 2014-03-28 | 2021-03-03 | ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション | Breast and ovarian cancer vaccines |
| CA2946563C (en) * | 2014-04-21 | 2019-03-12 | Becton Dickinson and Company Limited | Vial stabilizer base with connectable vial adapter |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
| US10039816B2 (en) | 2014-04-30 | 2018-08-07 | Massachusetts Institute Of Technology | Siderophore-based immunization against gram-negative bacteria |
| CN114805527A (en) | 2014-05-21 | 2022-07-29 | 哈佛大学的校长及成员们 | RAS inhibitory peptides and uses thereof |
| US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| CA2950415A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Anti-cd20 glycoantibodies and uses thereof |
| JP6894239B2 (en) | 2014-05-27 | 2021-06-30 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | Compositions and methods for universal glycoforms for enhanced antibody efficacy |
| CA2950440A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Anti-her2 glycoantibodies and uses thereof |
| TWI732738B (en) | 2014-05-28 | 2021-07-11 | 中央研究院 | Anti-tnf-alpha glycoantibodies and uses thereof |
| JP6664338B2 (en) | 2014-06-13 | 2020-03-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Immunogenic combination |
| MA40240B1 (en) | 2014-06-19 | 2019-03-29 | Ariad Pharma Inc | Heteroaryl compounds of kinase inhibition |
| WO2015200425A1 (en) | 2014-06-27 | 2015-12-30 | Topokine Therapeutics, Inc. | Topical dosage regimen |
| EP3164379A1 (en) | 2014-07-02 | 2017-05-10 | Massachusetts Institute of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
| EP3169699A4 (en) | 2014-07-18 | 2018-06-20 | The University of Washington | Cancer vaccine compositions and methods of use thereof |
| US10736966B2 (en) | 2014-08-12 | 2020-08-11 | Massachusetts Institute Of Technology | Brush-poly (glycoamidoamine)-lipids and uses thereof |
| WO2016040369A2 (en) | 2014-09-08 | 2016-03-17 | Academia Sinica | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS |
| USD757933S1 (en) | 2014-09-11 | 2016-05-31 | Medimop Medical Projects Ltd. | Dual vial adapter assemblage |
| SG10201902598VA (en) | 2014-09-24 | 2019-04-29 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and formulations thereof |
| CN112245565A (en) | 2014-09-24 | 2021-01-22 | 艾瑞朗医疗公司 | Peptidomimetic macrocycles and uses thereof |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| KR20210142781A (en) | 2014-10-21 | 2021-11-25 | 다케다 야쿠힌 고교 가부시키가이샤 | Crystalline forms of 5-chloro-n4-[2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidine-2,4-diamine |
| US20180015101A1 (en) | 2014-10-28 | 2018-01-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for antigen-specific tolerance |
| EP3461904A1 (en) | 2014-11-10 | 2019-04-03 | ModernaTX, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
| WO2016086026A1 (en) | 2014-11-26 | 2016-06-02 | Kala Pharmaceuticals, Inc. | Crystalline forms of a therapeutic compound and uses thereof |
| EP3230272B1 (en) | 2014-12-10 | 2020-08-19 | Kala Pharmaceuticals, Inc. | 1-amino-triazolo(1,5-a)pyridine-substituted urea derivative and uses thereof |
| WO2016105528A2 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| EP3237066B1 (en) | 2014-12-23 | 2020-10-21 | Sloan-Kettering Institute for Cancer Research | Polymorph of granaticin b |
| JP6358724B2 (en) | 2015-01-05 | 2018-07-18 | ウエスト・ファーマ．サービシーズ・イスラエル，リミテッド | Dual vial adapter assembly with easy removable pill adapter to ensure accurate use |
| US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
| WO2016118191A1 (en) | 2015-01-24 | 2016-07-28 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
| SG11201707750YA (en) | 2015-03-20 | 2017-10-30 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
| WO2016160617A2 (en) | 2015-03-27 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| CA2980172A1 (en) | 2015-03-30 | 2016-10-06 | Greenlight Biosciences, Inc. | Cell-free production of ribonucleic acid |
| JP1544111S (en) * | 2015-04-07 | 2016-02-22 | ||
| US10570104B2 (en) | 2015-04-27 | 2020-02-25 | University Of Florida Research Foundation, Incorporated | Metabolically programmed metal chelators and uses thereof |
| WO2016178591A2 (en) | 2015-05-05 | 2016-11-10 | Gene Predit, Sa | Genetic markers and treatment of male obesity |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| CN107848988B (en) | 2015-06-19 | 2021-10-22 | 麻省理工学院 | Alkenyl substituted 2, 5-piperazinediones and their use in compositions for delivering an agent to a subject or cell |
| WO2017004548A1 (en) | 2015-07-01 | 2017-01-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| CN113143759B (en) | 2015-07-16 | 2024-01-30 | 西部制药服务以色列有限公司 | Liquid drug transfer device for secure telescopic snap-fit on an injection vial |
| EP3347018B1 (en) | 2015-09-09 | 2021-09-01 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| JP2018528217A (en) | 2015-09-10 | 2018-09-27 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Peptidomimetic macrocycles as modulators of MCL-1 |
| CR20180199A (en) | 2015-09-11 | 2018-05-25 | Dana Farber Cancer Inst Inc | ACETAMIDE TIENOTRIAZOLODIAZEPINAS AND USES OF THE SAME |
| PE20181287A1 (en) | 2015-09-11 | 2018-08-07 | Dana Farber Cancer Inst Inc | CYANE HAS ANOTHRIAZOLPIRAZINES AND USES OF THE SAME |
| DK3350333T3 (en) | 2015-09-17 | 2022-01-31 | Modernatx Inc | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION |
| ES2910425T3 (en) | 2015-09-17 | 2022-05-12 | Modernatx Inc | Compounds and compositions for the intracellular delivery of therapeutic agents |
| EP3355882A1 (en) | 2015-10-01 | 2018-08-08 | Kythera Biopharmaceuticals, Inc. | Compositions comprising a statin for use in methods of adipolysis |
| GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
| USD801522S1 (en) | 2015-11-09 | 2017-10-31 | Medimop Medical Projects Ltd. | Fluid transfer assembly |
| JP6523569B2 (en) | 2015-11-25 | 2019-06-05 | ウエスト・ファーマ．サービシーズ・イスラエル，リミテッド | Dual vial adapter assembly comprising a vial adapter having a self sealing access valve |
| CN108472295B (en) | 2015-11-25 | 2022-04-15 | 达纳-法伯癌症研究所股份有限公司 | Bivalent bromodomain inhibitors and uses thereof |
| WO2017096238A1 (en) * | 2015-12-03 | 2017-06-08 | Drexel University | Medical fluid delivery system |
| SI3394030T1 (en) | 2015-12-22 | 2022-04-29 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| JP2019515876A (en) | 2016-03-08 | 2019-06-13 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | Methods for module synthesis of N-glycans and their arrays |
| US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
| WO2017176963A1 (en) | 2016-04-06 | 2017-10-12 | Greenlight Biosciences, Inc. | Cell-free production of ribonucleic acid |
| IL245803A0 (en) | 2016-05-24 | 2016-08-31 | West Pharma Services Il Ltd | Dual vial adapter assemblages including vented drug vial adapter and vented liquid vial adapter |
| IL245800A0 (en) | 2016-05-24 | 2016-08-31 | West Pharma Services Il Ltd | Dual vial adapter assemblages including identical twin vial adapters |
| MX2018014887A (en) | 2016-06-03 | 2019-06-06 | Sanofi Pasteur Inc | Modification of engineered influenza hemagglutinin polypeptides. |
| IL246073A0 (en) | 2016-06-06 | 2016-08-31 | West Pharma Services Il Ltd | Fluid transfer devices for use with drug pump cartridge having slidable driving plunger |
| US10105449B2 (en) | 2016-06-07 | 2018-10-23 | Massachusetts Institute Of Technology | Drug delivery polymers and uses thereof |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| JP2019525901A (en) | 2016-06-14 | 2019-09-12 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | Stabilized preparation of lipid nanoparticles |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| KR102467074B1 (en) | 2016-08-05 | 2022-11-11 | 사노피 파스퇴르 인코포레이티드 | Polyvalent pneumococcal polysaccharide-protein conjugate composition |
| BR112019001971A2 (en) | 2016-08-05 | 2019-05-07 | Sanofi Pasteur, Inc. | multivalent pneumococcal polysaccharide-protein conjugate composition |
| IL247376A0 (en) | 2016-08-21 | 2016-12-29 | Medimop Medical Projects Ltd | Syringe assembly |
| AU2017316663B2 (en) | 2016-08-22 | 2024-02-22 | CHO Pharma Inc. | Antibodies, binding fragments, and methods of use |
| WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| USD832430S1 (en) | 2016-11-15 | 2018-10-30 | West Pharma. Services IL, Ltd. | Dual vial adapter assemblage |
| WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
| IL249408A0 (en) | 2016-12-06 | 2017-03-30 | Medimop Medical Projects Ltd | Liquid transfer device for use with infusion liquid container and pincers-like hand tool for use therewith for releasing intact drug vial therefrom |
| WO2018170306A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| US20200129445A1 (en) | 2017-03-15 | 2020-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
| US11555031B2 (en) | 2017-03-20 | 2023-01-17 | The Broad Institute, Inc. | Compounds and methods for regulating insulin secretion |
| IL251458A0 (en) | 2017-03-29 | 2017-06-29 | Medimop Medical Projects Ltd | User actuated liquid drug transfer devices for use in ready-to-use (rtu) liquid drug transfer assemblages |
| BR112019020810A2 (en) | 2017-04-05 | 2020-04-28 | Biogen Ma Inc | tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof |
| EP3638678A1 (en) | 2017-06-14 | 2020-04-22 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| EP4327876A2 (en) | 2017-06-23 | 2024-02-28 | Affinivax, Inc. | Immunogenic compositions |
| WO2019013790A1 (en) | 2017-07-12 | 2019-01-17 | Curza Global, Llc | Antimicrobial compounds and uses thereof |
| WO2019013789A1 (en) | 2017-07-12 | 2019-01-17 | Curza Global, Llc | Antimicrobial compounds |
| CA3073211A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| IL254802A0 (en) | 2017-09-29 | 2017-12-31 | Medimop Medical Projects Ltd | Dual vial adapter assemblages with twin vented female vial adapters |
| AU2018347405B2 (en) | 2017-10-11 | 2022-02-03 | Greenlight Biosciences, Inc. | Methods and compositions for nucleoside triphosphate and ribonucleic acid production |
| JP7209710B2 (en) * | 2017-11-02 | 2023-01-20 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Container adapter, delivery assembly, and method of delivering liquid to a patient |
| US11786477B2 (en) | 2017-12-01 | 2023-10-17 | North Carolina State University | Fibrin particles and methods of making the same |
| GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| EP3793504B1 (en) * | 2018-05-17 | 2024-03-13 | Becton Dickinson France | Connector for connecting a medical injection device to a container |
| JP1630477S (en) | 2018-07-06 | 2019-05-07 | ||
| EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| CN113271926A (en) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | Preparation of lipid nanoparticles and methods of administration thereof |
| AU2020209167A1 (en) | 2019-01-16 | 2021-08-12 | Curza Global, Llc | Antimicrobial compounds and methods |
| EP3911644A1 (en) | 2019-01-16 | 2021-11-24 | Curza Global LLC | Antimicrobial compounds and methods |
| USD923812S1 (en) | 2019-01-16 | 2021-06-29 | West Pharma. Services IL, Ltd. | Medication mixing apparatus |
| JP1648075S (en) | 2019-01-17 | 2019-12-16 | ||
| CN113543761A (en) * | 2019-01-18 | 2021-10-22 | 西医药服务以色列有限公司 | Liquid delivery device for Intravenous (IV) bottles |
| EP3917486B1 (en) | 2019-01-31 | 2023-03-08 | West Pharma. Services IL, Ltd | Liquid transfer device |
| CA3128215A1 (en) | 2019-01-31 | 2020-08-06 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
| WO2020168466A1 (en) | 2019-02-19 | 2020-08-27 | Stemirna Therapeutics Co., Ltd. | Modified nucleoside and synthetic methods thereof |
| WO2020222220A1 (en) | 2019-04-30 | 2020-11-05 | West Pharma. Services IL, Ltd. | Liquid transfer device with dual lumen iv spike |
| US11604204B2 (en) | 2019-06-03 | 2023-03-14 | University Of Washington | Self-contained systems and methods for controlled dispensing of hazardous fluid |
| WO2021022173A1 (en) | 2019-07-31 | 2021-02-04 | Modernatx, Inc. | Compositions and methods for delivery of rna interference agents to immune cells |
| US20220265803A1 (en) | 2019-07-31 | 2022-08-25 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
| US11311458B2 (en) | 2019-09-11 | 2022-04-26 | B Braun Medical Inc. | Binary connector for drug reconstitution |
| CN115297930A (en) | 2019-11-13 | 2022-11-04 | 库扎环球有限责任公司 | Antimicrobial compounds and methods |
| CA3169669A1 (en) | 2020-01-31 | 2021-08-05 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
| WO2021173965A1 (en) | 2020-02-28 | 2021-09-02 | Massachusetts Institute Of Technology | Identification of variable influenza residues and uses thereof |
| WO2021231729A1 (en) | 2020-05-13 | 2021-11-18 | Sanofi | Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza |
| USD956958S1 (en) | 2020-07-13 | 2022-07-05 | West Pharma. Services IL, Ltd. | Liquid transfer device |
| EP4238979A1 (en) | 2020-10-30 | 2023-09-06 | Xeno-Interface Inc. | Beta-strand type crosslinked peptide |
| EP4238567A1 (en) | 2020-10-30 | 2023-09-06 | Keio University | Novel treatment and prevention of sarcopenia-related diseases |
| AR124267A1 (en) | 2020-12-09 | 2023-03-01 | Genentech Inc | HIGH THROUGH METHODS FOR PREPARING LIPID NANOPARTICLES AND THEIR USES |
| EP4305088A1 (en) | 2021-03-09 | 2024-01-17 | Massachusetts Institute of Technology | Branched poly(-amino esters) for the delivery of nucleic acids |
| TW202313065A (en) | 2021-05-28 | 2023-04-01 | 美商季卡尼醫療公司 | Compounds for treating genetic diseases |
| WO2023018817A1 (en) | 2021-08-11 | 2023-02-16 | Sanofi Pasteur Inc. | Truncated influenza neuraminidase and methods of using the same |
| US20230233667A1 (en) | 2021-09-08 | 2023-07-27 | Affinivax, Inc. | Coronavirus vaccine |
| CA3233926A1 (en) | 2021-10-08 | 2023-04-13 | Sanofi Pasteur Inc. | Multivalent influenza vaccines |
| WO2023081798A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi Pasteur Inc. | Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same |
| WO2023079113A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi | Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same |
| WO2023114889A1 (en) | 2021-12-16 | 2023-06-22 | Modernatx, Inc. | Processes for preparing lipid nanoparticles |
| WO2023129963A1 (en) | 2021-12-30 | 2023-07-06 | Curza Global, Llc | Antimicrobial compounds and methods |
| WO2023144206A1 (en) | 2022-01-27 | 2023-08-03 | Sanofi Pasteur | Modified vero cells and methods of using the same for virus production |
| WO2023177579A1 (en) | 2022-03-14 | 2023-09-21 | Sanofi Pasteur Inc. | Machine-learning techniques in protein design for vaccine generation |
| WO2023193002A1 (en) | 2022-04-01 | 2023-10-05 | Modernatx, Inc. | Cross mixers for lipid nanoparticle production, and methods of operating the same |
| WO2023235380A1 (en) | 2022-06-01 | 2023-12-07 | Zikani Therapeutics, Inc. | Macrolides for treating genetic diseases |
| WO2023250513A1 (en) | 2022-06-24 | 2023-12-28 | Zikani Therapeutics, Inc. | 13-membered macrolide compounds for treating diseases mediated by abnormal protein translation |
| US11547630B1 (en) * | 2022-07-21 | 2023-01-10 | Omar Hassad | Intravenous “Y” shaped (yaseen) adapter |
| WO2024026475A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses |
| WO2024026482A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Lipid nanoparticle compositions comprising surface lipid derivatives and related uses |
| WO2024026487A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Lipid nanoparticle compositions comprising phospholipid derivatives and related uses |
| WO2024049994A1 (en) | 2022-09-01 | 2024-03-07 | Zikani Therapeutics, Inc. | Treatment of familial adenomatous polyopsis using a 13-membered macrolide |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE681331C (en) * | 1937-05-04 | 1939-09-20 | Seitz Werke Gmbh | Bottle insert for filling devices |
| US2584397A (en) * | 1945-10-03 | 1952-02-05 | Louis K Pitman | Apparatus for transferring liquid from one container to another |
| US3580423A (en) * | 1969-02-27 | 1971-05-25 | Realistic Co | Container closure and apparatus for opening same |
| US3729031A (en) * | 1971-12-06 | 1973-04-24 | Mpl Inc | Liquid dispenser and plunger and method and apparatus for filling same |
| US3779371A (en) * | 1972-03-13 | 1973-12-18 | W Rovinski | Package of separated materials to be mixed |
| US3940003A (en) * | 1974-05-07 | 1976-02-24 | Pharmaco, Inc. | Safety cap for medicament vial having puncturable seal |
| US3938520A (en) * | 1974-06-10 | 1976-02-17 | Abbott Laboratories | Transfer unit having a dual channel transfer member |
| US4128098A (en) * | 1976-12-06 | 1978-12-05 | American Hospital Supply Corporation | Valved spike transfer device |
| US4516967A (en) * | 1981-12-21 | 1985-05-14 | Kopfer Rudolph J | Wet-dry compartmental syringe |
| SE456637B (en) * | 1982-04-13 | 1988-10-24 | Gambro Lundia Ab | HEATER RELIABLE CLUTCH |
| EP0107873B1 (en) * | 1982-10-27 | 1987-06-24 | Duphar International Research B.V | Hypodermic syringe having a telescopic assembly between cartridge and medicament holder |
| US4507113A (en) * | 1982-11-22 | 1985-03-26 | Derata Corporation | Hypodermic jet injector |
| US4515586A (en) * | 1982-11-30 | 1985-05-07 | Abbott Laboratories | Powder syringe mixing system |
| US4505709A (en) * | 1983-02-22 | 1985-03-19 | Froning Edward C | Liquid transfer device |
| AU575814B2 (en) * | 1983-03-03 | 1988-08-11 | Bengt Gustavsson | A device for transferring a substance |
| US4543101A (en) * | 1984-03-28 | 1985-09-24 | Adria Laboratories, Inc. | Valve device to aid in reconstituting injectable powders |
| US4581014A (en) * | 1984-04-03 | 1986-04-08 | Ivac Corporation | Fluid infusion system |
| US5088996A (en) * | 1984-04-16 | 1992-02-18 | Kopfer Rudolph J | Anti-aerosoling drug reconstitution device |
| US4607671A (en) * | 1984-08-21 | 1986-08-26 | Baxter Travenol Laboratories, Inc. | Reconstitution device |
| US4759756A (en) * | 1984-09-14 | 1988-07-26 | Baxter Travenol Laboratories, Inc. | Reconstitution device |
| US4614437A (en) * | 1984-11-02 | 1986-09-30 | Dougherty Brothers Company | Mixing container and adapter |
| US4675020A (en) * | 1985-10-09 | 1987-06-23 | Kendall Mcgaw Laboratories, Inc. | Connector |
| US4662878A (en) * | 1985-11-13 | 1987-05-05 | Patents Unlimited Ltd. | Medicine vial adaptor for needleless injector |
| US4886495A (en) * | 1987-07-08 | 1989-12-12 | Duoject Medical Systems Inc. | Vial-based prefilled syringe system for one or two component medicaments |
| US4940460A (en) * | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
| US4941880A (en) * | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4768568A (en) * | 1987-07-07 | 1988-09-06 | Survival Technology, Inc. | Hazardous material vial apparatus providing expansible sealed and filter vented chambers |
| IT1231892B (en) * | 1987-10-14 | 1992-01-15 | Farmitalia Carlo Erba S P A Mi | APPARATUS WITH SAFETY LOCKING ORGANS FOR CONNECTION OF A SYRINGE TO A BOTTLE CONTAINING A DRUG |
| US5211638A (en) * | 1988-01-25 | 1993-05-18 | Baxter International Inc. | Pre-slit injection site |
| US5100394A (en) * | 1988-01-25 | 1992-03-31 | Baxter International Inc. | Pre-slit injection site |
| US4913699A (en) * | 1988-03-14 | 1990-04-03 | Parsons James S | Disposable needleless injection system |
| JPH021277A (en) * | 1988-03-31 | 1990-01-05 | Fujisawa Pharmaceut Co Ltd | Infusion container |
| BR8801952A (en) * | 1988-04-22 | 1989-11-14 | Sergio Landau | DISPOSABLE CAPSULE, NOT RE-USABLE, CONTAINING INDIVIDUAL DOSE OF VACCINE TO BE HYPODERMICALLY INJECTED, WITHOUT NEEDLE, WITH PRESSURE INJECTOR |
| US5195992A (en) * | 1988-05-13 | 1993-03-23 | Baxter International Inc. | Protector shield for needles |
| US4944736A (en) * | 1989-07-05 | 1990-07-31 | Holtz Leonard J | Adaptor cap for centering, sealing, and holding a syringe to a bottle |
| US4997430A (en) * | 1989-09-06 | 1991-03-05 | Npbi Nederlands Produktielaboratorium Voor Bloedtransfusieapparatuur En Infusievloeistoffen B.V. | Method of and apparatus for administering medicament to a patient |
| US5312335A (en) * | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5304165A (en) * | 1991-12-09 | 1994-04-19 | Habley Medical Technology Corporation | Syringe-filling medication dispenser |
| US5163583A (en) * | 1992-01-03 | 1992-11-17 | Whitworth Ted N | Aspiration cap for dispensing blood or other fluids for diagnostic purposes |
| US5281198A (en) * | 1992-05-04 | 1994-01-25 | Habley Medical Technology Corporation | Pharmaceutical component-mixing delivery assembly |
| US5312577A (en) * | 1992-05-08 | 1994-05-17 | Bioject Inc. | Method for manufacturing an ampule |
| US5279576A (en) * | 1992-05-26 | 1994-01-18 | George Loo | Medication vial adapter |
| US5383851A (en) * | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5334179A (en) * | 1992-10-16 | 1994-08-02 | Abbott Laboratories | Latching piercing pin for use with fluid vials of varying sizes |
| US5364386A (en) * | 1993-05-05 | 1994-11-15 | Hikari Seiyaku Kabushiki Kaisha | Infusion unit |
| US5360423A (en) * | 1993-05-25 | 1994-11-01 | Mccormick William | Means for safe collection and transfer of body fluids |
| US5472022A (en) * | 1993-11-02 | 1995-12-05 | Genentech, Inc. | Injection pen solution transfer apparatus and method |
| DE4408498C2 (en) * | 1993-11-16 | 1997-06-12 | Christian Eichler | Transfer device for medicine and pharmacy |
| US5505697A (en) * | 1994-01-14 | 1996-04-09 | Mckinnon, Jr.; Charles N. | Electrically powered jet injector |
| US5466220A (en) * | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
| US5526853A (en) * | 1994-08-17 | 1996-06-18 | Mcgaw, Inc. | Pressure-activated medication transfer system |
| US5647845A (en) * | 1995-02-01 | 1997-07-15 | Habley Medical Technology Corporation | Generic intravenous infusion system |
-
1996
- 1996-01-12 US US08/586,566 patent/US5893397A/en not_active Expired - Lifetime
- 1996-12-11 CA CA 2192623 patent/CA2192623C/en not_active Expired - Fee Related
- 1996-12-20 PT PT96309337T patent/PT783879E/en unknown
- 1996-12-20 DK DK96309337T patent/DK0783879T3/en active
- 1996-12-20 EP EP19960309337 patent/EP0783879B1/en not_active Expired - Lifetime
- 1996-12-20 ES ES96309337T patent/ES2200041T3/en not_active Expired - Lifetime
- 1996-12-20 DE DE1996628275 patent/DE69628275T2/en not_active Expired - Lifetime
- 1996-12-20 AT AT96309337T patent/ATE240709T1/en not_active IP Right Cessation
- 1996-12-24 JP JP34331296A patent/JP3916713B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE240709T1 (en) | 2003-06-15 |
| DK0783879T3 (en) | 2003-09-15 |
| DE69628275T2 (en) | 2004-04-01 |
| EP0783879A3 (en) | 1997-11-26 |
| JPH09290012A (en) | 1997-11-11 |
| DE69628275D1 (en) | 2003-06-26 |
| JP3916713B2 (en) | 2007-05-23 |
| EP0783879A2 (en) | 1997-07-16 |
| ES2200041T3 (en) | 2004-03-01 |
| US5893397A (en) | 1999-04-13 |
| PT783879E (en) | 2003-09-30 |
| EP0783879B1 (en) | 2003-05-21 |
| CA2192623A1 (en) | 1997-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2192623C (en) | Medication vial/syringe liquid/transfer apparatus | |
| US5364387A (en) | Drug access assembly for vials and ampules | |
| EP1145702B1 (en) | Adapter for mixing and injection of preparations | |
| US5232029A (en) | Additive device for vial | |
| CA1296296C (en) | Connector and disposable assembly utilizing said connector | |
| US4505709A (en) | Liquid transfer device | |
| US5632315A (en) | Liquid dispensers | |
| US3788524A (en) | Additive container | |
| JP4163961B2 (en) | Kit including a side-spout syringe needle for preparing medication in an infusion pen cartridge | |
| US7425208B1 (en) | Needle assembly facilitating complete removal or nearly complete removal of a composition from a container | |
| US5356380A (en) | Drug delivery system | |
| US7678333B2 (en) | Fluid transfer assembly for pharmaceutical delivery system and method for using same | |
| US4599082A (en) | Two-component syringe assembly | |
| CA2221434C (en) | Syringe filling and delivery device | |
| EP0357288A1 (en) | Device for storage, mixing and dispensing of two different fluids | |
| US4775376A (en) | Method and apparatus for catching fluids purged from a syringe | |
| CA2071280A1 (en) | Transfer adaptors | |
| KR980008252A (en) | Syringe Filling and Carrying Device | |
| US20150101708A1 (en) | Inter-vial transfer system | |
| JPS6072561A (en) | Two-drug component syringe having vein display capacity | |
| JPH05146510A (en) | Pressure injection type vessel soluble upon application | |
| CN217909831U (en) | Needleless medicine dispensing device | |
| CN110236943A (en) | It is a kind of to shift filter with the medical fluid of cam pin and filter structure | |
| EP3911292B1 (en) | Liquid transfer devices for use with intravenous (iv) bottles | |
| WO2011092513A2 (en) | An assembly for delivering a fluid drug and method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20141211 |